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General Introduction
GENERAL INTRODUCTION
Psoriasis vulgaris
Today, psoriasis vulgaris is recognized as the most prevalent autoimmune disease 
caused by inappropriate activation of the cellular immune system.[1] It is a chronic, prolif-
erative, and inflammatory skin disease characterized by sharply demarcated red plaques 
with white scales. Of the many clinical forms of the disease, chronic plaque psoriasis 
(psoriasis vulgaris) is by far the most common type. The typical histological appearance 
of psoriasis includes the hyperproliferation and aberrant differentiation of epidermal ke-
ratinocytes, dermal infiltration of immunocytes (particularly T-lymphocytes, monocytes, 
and neutrophils), and hyperplastic blood vessels, which lead to the excessive thickening 
and scaling of the erythematous skin[2] (Figure 1). Both the rapid epidermal proliferation 
and dermal inflammatory infiltration are accompanied by the formation of numerous 
new blood vessels, which starts during the early changes of psoriasis and vanishes after 
skin lesion clearance.[3] 
Psoriasis is a serious skin disease that affects a person’s daily life on many levels, includ-
ing the individual’s professional and social life. The physical and psychological impacts 
of psoriasis are comparable to those of cancer, heart disease, diabetes, or depression.[4]
Pathophysiology
Psoriasis is a T-cell mediated inflammatory condition of the skin. We believe that it 
is a combination of genetic and environmental factors such as stress, specific drugs, 
trauma, smoking, or infection with streptococci that triggers a cascade of immuno-
logical reactions resulting in inflammation of the skin. Plasmacytoid dendritic cells and 
keratinocytes produce pro-inflammatory cytokines such as interferon-α, interleukin-1, 
interleukin-6, tumor necrosis factor-alpha (TNFα), and chemokines. These activate the 
myeloid dendritic cell, which in turn presents antigens and secretes interleukins, leading 
to the differentiations of Th-1 and Th-17 helper cells. The T cells then secrete mediators 
that activate keratinocytes and induce the production of antimicrobial peptides, proin-
flammatory cytokines, and chemokines. These processes maintain the inflammation in 
psoriasis.[3]
Continuous research on mediators of inflammation in psoriasis, such as IL-12, IL-23, IL-
17, Janus kinases (JAK), and phosphodiesterase 4 (PDE4), has become important for the 
development of new targets for antipsoriatic therapy.[6] Recently, an imbalance of skin 
and gut microbiomes has been shown to play a role in skin diseases such as psoriasis.
[7-9] Staphylococci and Propionibacteria have shown to be significantly lower in psoriatic 
skin compared to healthy skin.[10, 11] 
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CLINICAL PHENOTYPES OF PSORIASIS
Psoriasis is an erythemato-papulo-squamous skin disease with variable morphology, 
distribution, severity, and course. Despite the classic presentation, the morphology can 
Figures 1. Histopathological features of psoriasis
Reprinted from The Lancet, WH Boehncke, MP Schoen, Psoriasis, 2015, with permission from Elsevier.
The typical plaque shows marked epidermal acanthosis, hyperkeratosis, and an elongation of rete ridges 
(A, normal skin and B, lesional psoriatic skin; stained with haematoxylin and eosin). The dermis shows di-
lated and contorted dermal blood vessels that reach into the tips of the dermal papillae (B, arrows). There, 
a mixed inflammatory infiltrate with neutrophils accumulating within the epidermis is noted (B, asterisk). 
Compared to normal skin (C), the immunohistochemical detection of CD3 reveals many T cells in the dermis 
and epidermis of lesional psoriatic skin (D, arrows). Another characteristic of lesional psoriatic skin is that 
the cell nuclei are present in the cornified layer of the epidermis (D, asterisk).[5]
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range from small tear-shaped papules (guttate psoriasis) to pustules (pustular psoriasis) 
and generalized erythema and scale (erythrodermic psoriasis). In addition, these dif-
ferent forms of psoriasis may be localized or widespread and disabling. Furthermore, 
psoriasis may follow a variable course, presenting as chronic, stable plaques or acutely, 
with a rapid progression and widespread involvement. Psoriasis can be symptomatic, 
with patients complaining of intense pruritus or burning. The various types and presen-
tations of psoriasis are outlined below.
Plaque psoriasis
As the most common form of psoriasis, representing almost 90% of psoriatic patients, 
plaque psoriasis is also known as psoriasis vulgaris.[12] Patients may have sharply 
circumscribed, round-oval, or nummular plaques. The lesions may initially begin as 
erythematous macules (flat and <1 cm) or papules, extend peripherally, and coalesce to 
Figure 2. Immune pathogenesis of psoriasis
Reprinted from The Lancet, WH Boehncke, MP Schoen, Psoriasis, 2015, with permission from Elsevier.[5]
The pathological changes in pre-psoriatic skin involve a complex interplay of cutaneous cell types, which is 
dependent on macrophages, dendritic cells, T cells, and other cells of the immune system, including many 
cytokines and chemokines. The differentiation of Th1 and Th17 cells is stimulated by dendritic cells through 
IL-23 (A). T cells and cells of the innate immune system (macrophages, mast cells, granulocytes) produce 
several mediators that induce and maintain psoriatic hallmark features in both the dermis (e.g., endothe-
lial cells) and epidermis (keratinocytes). In turn, the latter cell types facilitate the inflammatory response 
through their mediators (B). IL=interleukin. TNF=tumor necrosis factor. IFN=interferon.
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form plaques of one to several centimeters in diameter. A white blanching surrounding 
ring, known as Woronoff ’s ring, may be observed.[13] 
Scale, which is typically present in psoriasis, is characteristically silvery white and can 
vary in thickness. Removal of the scale may reveal tiny bleeding points (Auspitz sign). 
Another well-known feature of psoriasis is the Koebner phenomenon, whereby new 
lesions may appear in a patient with psoriasis following direct cutaneous trauma.
Guttate psoriasis
Guttate psoriasis, from the Greek word gutta meaning a droplet, describes the acute on-
set of a myriad of small lesions of psoriasis that are 2–10 mm in diameter. These lesions 
are usually distributed in a centripetal fashion, although guttate lesions can also involve 
the head and limbs. Classically, guttate psoriasis occurs shortly after an acute group B 
hemolytic streptococcal infection of the pharynx or tonsils and can be the presenting 
episode of psoriasis in children or, occasionally, adults. The number of lesions may range 
from five or 10 to more than 100. Guttate psoriasis accounts for 2% of all cases of psoria-
sis and is often the first episode of psoriasis for the patient.
Flexural (inverse) psoriasis
Psoriasis affecting the flexures, particularly inframammary, genital, perineal, and axillary, 
is morphologically distinct from traditional plaques elsewhere on the trunk and limbs. 
Flexural lesions appear as red, shiny, well-demarcated plaques without the characteristic 
desquamation and are occasionally confused with candidal, intertrigo, and dermato-
phyte infections by non-dermatologists.[13] Flexural psoriasis is the first form of psoriasis 
appearing in children.
Erythrodermic psoriasis
Erythrodermic psoriasis generally develops if there is poor control of a patient’s existing 
psoriasis. Abrupt withdrawal of systemic medication (e.g., corticosteroids) as a response 
to a drug reaction (e.g., lithium) or due to an underlying systemic infection may impair 
the thermoregulatory capacity of the skin, leading to hypothermia, high-output cardiac 
failure, and metabolic changes including hypoalbuminemia and anemia due to the loss 
of iron, vitamin B12, and folate.94,95 Secondary infection is common and can lead to sepsis. 
Erythodermic psoriasis is a serious condition and acquires acute professional care. 
Pustular psoriasis 
Generalized pustular psoriasis is a rare but serious disease and presents as different clinical 
subtype with a different genetic background. It is caused by an interleukin 36 deficiency. 
Initially it shows scattered, subsequently confluent pustules together with fever and gen-
eralized lymphadenopathy. This is also known as von Zumbusch psoriasis.[14]
15
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Sneddon-Wilkinson disease, also known as subcorneal pustular dermatosis, is a chron-
ic, relapsing disease presenting pustules and vesicles that move peripherally, forming 
an annular pattern.[15] The flexural and intertriginous areas are most commonly affected. 
The pathogenesis of this disease is related to increased production of tumor necrosis 
factor-α, which leads to a neutrophil infiltration of the skin. Whether Sneddon-Wilkinson 
disease is a less severe variant of pustular psoriasis is an ongoing controversy; however, 
patients with pustular psoriasis usually seem more ill and might be febrile.
Palmoplantar pustulosis 
Although Palmoplantar pustulosis is often regarded as a subtype, it is a genetically distinct 
disease that may represent an independent disease entity. It is characterized by fresh yel-
low and older brownish pustules that appear exclusively on the palms and/or soles.[16]
Acrodermatitis continua suppurativa (Hallopeau) 
Pustules with severe inflammation on the tips of the fingers and/or toes, often rapidly leading 
to damage to the nail matrix and nail loss, are the clinical characteristics of this rare variant of 
pustular psoriasis. The distal phalanges may be destroyed during the course of the disease.[17]
Arthritis psoriatica
Psoriatic arthritis (PsA), a chronic inflammatory arthritis, affects about 10% of patients 
with psoriasis overall, with a higher prevalence in patients with more extensive skin 
disease and a prevalence as high as 30% in dermatology clinics (where patients tend to 
have more extensive/severe psoriasis).[18-22] Methotrexate has been used to treat PsA for 
more than 40 years due to its efficacy and low costs. TNF blockade with biologics, or the 
combination of these therapies, is considered the first-line treatment for patients with 
moderate to severely active PsA.
GENETICS
Proof of familial aggregation is the first step in pursuing a possible genetic susceptibil-
ity in a disease. Family and twin studies have clearly demonstrated that psoriasis has 
a strong genetic basis.[23] Genomic imprinting is an epigenetic effect that causes the 
differential expression of a gene depending on the sex of the transmitting parent.[24] 
A family study from the Faroe Islands reported a higher penetrance of psoriasis if the 
father was affected or a presumed gene carrier.[25] Psoriasis shows a clear association 
with certain alleles of the HLAC gene and specifically with the HLA-Cw6 allele (known as 
HLA-Cw*0602 when identified through high-resolution genotyping), present in 30% of 
psoriasis patients (compared with between 10% and 15% in the general population).[26]
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EPIDEMIOLOGY
Psoriasis is universal in occurrence, although the worldwide prevalence varies between 
0.6% and 4.8%.[4] The prevalence of psoriasis in people of Caucasian descent is approxi-
mately 2%.[27] In the Netherlands, an estimated 300,000 people have been diagnosed as 
having psoriasis. Its prevalence is equal in men and women and may begin throughout 
life, but two peaks have been identifi ed in terms of age of onset: one occurring at 15–25 
years old and another later one at around 50–60 years.[17, 28-31] Patients with early onset 
psoriasis have a tendency (P < 0.5) to experience obesity, diabetes, dyslipidaemia, hy-
pertension, and major cardiovascular events (MACE) at higher frequencies.
Plaque psoriasis Guttate psoriasis
Flexural (inverse) psoriasis
Erythrodermic psoriasisAcrodermatitis continua suppurativa (hallopeau)
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SEVERITY ASSESSMENTS
Various tools are available for measuring the severity of plaque psoriasis. The most 
widely used measure is the Psoriasis Area and Severity Index (PASI). According to recent 
guidelines, moderate to severe disease is defined as having a PASI score >10.[32] PASI 75 
and PASI 90 responses are dynamic parameters that indicate the percentage of patients 
who have achieved an at least 75% or 90% improvement in their baseline PASI score 
during treatment, respectively. Other measures frequently used to quantify disease se-
verity in psoriasis are the Physician’s Global Assessment (PGA) of disease severity, which 
is based on the measures also encompassed in the PASI, and body surface area (BSA), 
which represents the percentage of the body surface affected by psoriasis.[16] The BSA is 
a quick and easy assessment tool for dermatologists to use in their daily practice. 
QUALITY OF LIFE
Different questionnaires have been developed to measure the impact of psoriatic 
disease on patients. To be able to address this matter, it is important to evaluate patient-
reported outcome measures (PROMs) such as health-related quality of life (HRQoL)[33]; 
these differ from one another based on their generic (SF-36, Euro Qol 5D),[34],[35] disease-
specific (DLQI, Skindex-29),[36] or psoriasis-related (PsoQol, PDI) approaches.[16] 
PSORIASIS AND COMORBIDITIES
Relatively well-studied possible comorbidities in psoriasis are malignancies,[37-41] infec-
tions,[42, 43] non-alcoholic fatty liver disease,[44, 45] osteoporosis,[46] inflammatory bowel 
disease,[47],[48] , COPD [49]  and  major adverse cardiovascular events [50, 51] . The concept of 
comorbidity in psoriasis is based on the hypothesis that psoriasis not only leads to skin 
inflammation, but also causes systemic inflammation mediated by inflammatory markers 
such as interleukins and TNFα circulating in the serum.[52] These may alter the function 
of hepatocytes, endothelial cells, atheroma, and thrombus risk, leading to an increase in 
cardiovascular risk factors. This “psoriatic march” can eventually lead to atherosclerosis 
and finally to cardiovascular events.[50, 51] Another hypothesis is that components of the 
metabolic syndrome are risk factors for psoriatic disease.[51] Smoking, obesity, and high 
waist circumference can increase the risk of incident of psoriasis.[53, 54]
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THERAPIES
Since the epidemiological circumstances surrounding disease debut and the pathoge-
netic mechanisms inducing the psoriasis skin phenotype are not clearly understood, 
to date its treatment is non-curative and its goal is to mitigate disease severity and 
symptoms. Four treatment modalities exist. In increasing order of potency, they are 
divided into topical therapy, phototherapy, systemic therapy, and biologics. Choices of 
treatments have to be customized to the patient and are influenced by factors such as 
disease severity (PASI > or < 10) with or without psoriatic arthritis, clinical phenotypes 
(psoriasis vulgaris, psoriasis guttata, psoriasis pustulosa, psoriasis inversa, erythroder-
mic psoriasis), and recalcitrance as well as patient preferences and patient compliance 
and adherence. Adherence is crucial for the efficacy of chronic treatments. Patients must 
be actively involved in the choice of the product, formulation, and mode of application.
[55] Although there is a wide variety of treatment options available, there is still a need 
for a simple, safe, and effective long-term therapy. In addition, modern therapy with 
biologics is expensive; therefore, there is a great need for an effective, safe, long-term, 
and low-cost treatment.
TOPICAL THERAPIES
Topical therapy is considered first-line therapy for the majority of patients with mild 
plaque psoriasis. Most patients on systemic treatments also benefit from concurrent 
topical treatment for the greatest clearance of disease. First-line management of mild 
psoriasis involves topical treatment, primarily with corticosteroids and vitamin D ana-
logues. However, with topical products, non-adherence is further exacerbated by the 
need for application, which can be cumbersome and time-consuming, combined with 
patients’ poor acceptability of certain treatment vehicles, such as ointments, which are 
perceived as messy.[56-63] Topical corticosteroid use can be limited by local and systemic 
adverse effects, such as the atrophy of the skin and tachyphylaxy, especially if higher 
potency corticosteroids are used over the long term. Vitamin D analogues are more 
likely than corticosteroids to cause local skin irritation, and their use can be limited in 
terms of the application amount and body region.[64] Head-to-head studies with topical 
corticosteroids have shown that Vitamin D3 analogues such as calcipotriol are as effec-
tive, except for when calcipotriol is compared to a combination of potent corticosteroids 
and calciptriol. Coal tar and dithranol are some of the oldest topical treatments used 
in psoriasis patients; however, they are less commonly used due to side effects such as 
local skin irritation and the staining of skin and clothing.[65, 66] Topical retinoids such as 
tazarotene (not available in the Netherlands) modulate keratinocyte proliferation and 
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differentiation and are anti-inflammatory, but also cause irritation and erythema at the 
site of application; therefore, they are not commonly used.[67-69] Tacrolimus can be used 
to treat facial psoriasis. 
Phototherapy and photochemotherapy
Historically, Balneo-phototherapy at the Dead Sea has been shown to be a beneficial 
treatment for most patients with psoriasis. Its clinical effect is based on the very high 
concentration and special salt contents of the Dead Sea water in combination with 
sunlight. Results of in vitro and in vivo studies have shown that narrow-band ultraviolet 
B (UVB) light and Dead Sea salt together have a multiple, synergistic effect on psoriatic 
skin. Both are effective in reducing the number and activity of Langerhans cells.[70]
Narrowband UVB (NBUVB) and psoralen ultraviolet A (PUVA) therapy cause the deple-
tion of cells involved in the pathogenesis of psoriasis, including lymphocytes, macro-
phages, and dendritic cells.[71, 72] NBUVB has proven to be more effective than broadband 
UVB (BBUVB).[73] The maximum dose depends on the minimal erythema dose (MED), and 
patients are treated two or three times a week. PUVA monotherapy refers to the use 
of 8-methoxypsoralen, which sensitizes the cells to the effects of longer-wave-length 
UV light and can be administered topically or orally.[16] Cyclosporine greatly increases 
the risk of squamous cell carcinoma in patients with psoriasis who have been exposed 
to PUVA.[74] Although the role of PUVA therapy in skin carcinogenesis in patients with 
psoriasis has been well documented, there is still uncertainty regarding the risk of skin 
cancer with BBUVB and NBUVB. It has been estimated that the increased annual risk 
of non-melanoma skin cancer (NMSC) associated with UVB radiation was likely to be < 
2%.[70]
Photodynamic therapy (PDT)
Photodynamic therapy (PDT) is a technique that involves the delivery of a photosensi-
tive agent to targeted areas of the skin, leading to selective cell death upon irradiation 
with visible light. Since the early 1900s, clinical applications have included the treat-
ment of skin malignancies, lupus vulgaris, syphilis, molluscum contagiosum, pityriasis 
versicolor, and psoriasis.[75] In 1994, Boehncke et al. reported complete clearance of 
psoriatic plaques treated with topical ALA and PDT in three patients.[76] The specific 
mechanism behind PDT for psoriasis is not completely known, but evidence suggests 
that key components involve the apoptosis of lesional T-lymphocytes and inhibition of 
inflammatory cytokines (TNF-a, IL-1, and IL-6).[77] Early reports on the complete clearance 
of plaques after topical ALA–PDT application were promising for the birth of a new pho-
totherapeutic modality for psoriasis. However, as more research has been performed, 
including randomized, blinded, and placebo-controlled studies, the clinical efficacy of 
topical ALA–PDT use was underwhelming and inconsistent. Compounding the relatively 
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unimpressive clinical results, the painful side effect of topical ALA–PDT application is 
another major drawback to its use.[78]
Pulsed dye laser therapy
The flash lamp pumped pulsed dye laser (PDL) was the first laser specifically developed 
for the treatment of vascular lesions. The mode of action of the PDL is based on the 
principle of selective photothermolysis, a targeted damaging of specific structures in 
the skin, without damaging the surrounding area, through direct cutaneous immuno-
logic activation.[79-81] Clinical studies describing the treatment of localized psoriasis have 
mostly concerned chronic, stable plaque psoriasis, sometimes explicitly described as 
recalcitrant, that does not respond to conventional therapy such as potent topical ste-
roids, UVB, psoralen plus UVA, and tar.[82-89] No large RCT (randomized controlled trials) 
on the efficacy of PDL for psoriasis were performed. Practically, PDL treatment is limited 
to a few psoriasis plaque lesions resistant to conventional therapy. [12]
SYSTEMIC THERAPY
Methotrexate
Methotrexate (MTX) has been used in the treatment of psoriasis since 1958 and is widely 
employed in Europe.[90] In dermatology, methotrexate is used most frequently for the 
treatment of moderate to severe plaque-type psoriasis, especially in cases with joint 
involvement or in pustular or erythrodermic forms.[91] MTX, an analogue of folic acid, 
competitively inhibits the enzyme dihydrofolate reductase and several other folate 
dependent enzymes. The main effect of methotrexate is the inhibition of thymidylate 
and purine synthesis, resulting in decreased synthesis of DNA and RNA. The inhibition 
of nucleic acid synthesis in activated T cells and in keratinocytes is believed to account 
for the antiproliferative and immunomodulatory effects of methotrexate, which are 
considered the main mechanisms of the therapeutic effect of methotrexate in psoriasis 
vulgaris.[16] Nevertheless, methotrexate has severe adverse events. The two most impor-
tant adverse reactions are myelosuppression and irreversible hepatotoxicity. These side 
effects are dose-dependent. 
Multiple stresses on the hepatocyte, such as diabetes, obesity, and overconsumption 
of alcohol, which are features of the metabolic syndrome psoriasis patients frequently 
have, appear to contribute to the development of fibrosis. Recently, van der Voort et al. 
demonstrated that psoriasis is independently associated with nonalcoholic fatty liver 
disease in patients 55 years old or older.[45] Some have speculated that patients with 
psoriasis drink more alcohol, which may explain why liver damage occurs more often 
in patients with psoriatic than rheumatoid conditions. Another reason why methotrex-
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ate is widely used as the “golden standard” for psoriasis is that it is more cost-effective, 
especially compared to biologics.
Ciclosporine
Ciclosporine is a calcineurin inhibitor and immune modulator that inhibits the produc-
tion of pro-inflammatory cytokines and the activity of T-lymphocytes. The European 
guidelines recommend ciclosporine primarily for induction therapy due to its rapid 
efficacy and long-term side effects. The clinical improvement of psoriasis occurs after 
approximately 4 weeks, and maximum response is seen after about 8 to 16 weeks. The 
efficacy is dose-dependent, and the PASI 75 response is 50% at 8 weeks with a daily dose 
of 3mg/kg.[16]
Studies comparing high-dose ciclosporine (5 mg/kg) with low-dose cyclosporine 
(2.5–3 mg/kg) have indicated a higher efficacy with high-dose ciclosporine. In head-to-
head trials, ciclosporine was superior to etretinate, superior to 7.5 mg of MTX weekly, 
and similar in efficacy to 15 mg of MTX weekly. Nevertheless, the use of cyclosporine 
is limited by its side effects, such as nephrotoxicity. The benefit/risk ratio appears to be 
better for patients without risk factors for nephrotoxicity—namely, non-obese patients 
without hypertension who are younger than 60 years of age.[92]
Acitretin
Oral retinoids such as acitretin have antiproliferative and anti-inflammatory properties. 
They have teratogenic properties and therefore cannot be administered in women of 
childbearing age. The most common side effects are mucocutaneous dryness and hy-
perlipidemia. Acitretin is not recommended as a first choice in monotherapy for plaque 
psoriasis; however, its use in combination with topical calcipotriol or phototherapy (Re-
UVB or Re-PUVA) has proven effective.[93]
Phosphodiesterase 4 inhibitor 
In March 2014, the Food and Drug Administration (FDA) approved apremilast (Otezla, 
Celgene Corporation), the first selective inhibitor of phosphodiesterase 4 (PDE4) indi-
cated for adults with active PsA. Advantages to the use of apremilast include its oral 
administration, minimal drug interaction potential, and what appears to be a fairly safe 
AE profile, particularly compared to the profiles of methotrexate and biologics. The cost 
of apremilast is also lower than that of biologics. Nevertheless, the twice-daily dosing 
might not be advisable if nonadherence is a concern, and the gastrointestinal side ef-
fects may be troublesome.
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Biologics
As recently as a decade ago, psoriasis pathophysiology was thought to begin with a 
yet-to-be identifi ed antigen, which was transported by an antigen-presenting cell to a 
skin-draining lymph node, wherein T-cell activation began. The T cells were believed to 
be transported back to the skin through the vasculature and, upon re-entry, to trigger 
the release of infl ammatory mediators, including tumor necrosis factor (TNF)-α. This 
conceptual framework of psoriasis led to the development of fi rst-generation biologic 
agents, alefacept and efalizumab, which targeted T-cell activation.[3] Efalizumab was 
approved in 2003, but was withdrawn from the market in 2009 due to the increased 
risk of progressive multifocal leukoencophalopathy. Many other biologicals followed: 
the TNFα antagonist adalimumab, etanercept and infl iximab, and the interleukin-12/23 
antagonist ustekinumab. These therapies attain a PASI 75 response varying from 30% to 
80% at 12 weeks. A recently published study showed no signifi cant diff erence in drug 
survival, mean PASI change, or Skindex-29 response among etanercept, adalimumab, 
and ustekinumab at 12 or 52 weeks.[94] As these drugs are being administered to pa-
tients, new biologic treatments emerge aiming at inhibiting novel and already known 
pathways involved in psoriasis. Recent examples are the anti-interleukin-17A receptor 
antibodies secukinumab, brodalumab, and ixekizumab.
Although biologic agents have clinically proven effi  cacy, their use is associated with 
a much higher cost compared with traditional treatment options, and long-term safety 
aspects are still not well known. This is why fumarates hold a special place in the treat-
ment of psoriasis, which we thought to mention as the last systemic therapy.
Fumarates
Fumarates (FAE), which are ester derivatives of fumaric acid, are small molecules with 
immunomodulating properties.[95] FAE were fi rst described as an oral anti-psoriatic treat-
ment by the German chemist Schweckendick in 1959.[40] Treatment with FAE was further 
developed in Switzerland in the 1970s and 1980s.[41] The fi rst randomized clinical trials 
with oral FAE were published in the early 1990s, and in 1994 treatment with FAE became 
approved in Germany for the treatment of adult patients with severe psoriasis. Fourteen 
years later, in 2008, the approved indication of FAE was extended to include patients 
with moderate psoriasis.[96] The licensed fumarate formulation in Germany is Fumaderm 
(Biogen Idec GmbH, Ismaning, Germany), which consists of a mixture of the fumarates 
dimethylfumarate (DMF) and monoethylfumarate (MEF) in two strengths: Fumaderm 
initial 105 mg tablets containing 30 mg of DMF and 75 mg of MEF, and Fumaderm 215 mg 
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tablets containing 120 mg of DMF and 95 mg of MEF. Fumaderm is dosed according to a 
standardized incremental dosage regimen up to 215 mg of Fumaderm six times a day.[3]  
To date, Fumaderm is one of the most prescribed systemic treatments for psoriasis in 
Germany.[43] In other European countries, like the Netherlands and the United Kingdom, 
the use of FAE for the treatment of moderate to severe psoriasis has been increasingly 
reported, although their use in these countries remains unlicensed. In the Netherlands, 
FAE are not approved, but regarded and reimbursed as a rational pharmacotherapy for 
psoriasis. Several standardized but unlicensed Dutch FAE formulations are in use in the 
Netherlands, containing either DMF and calcium-MEF, DMF, or DMF through slow release. 
The mechanism of action by which FAE improve psoriasis is only partially understood. 
The major mechanism of action is thought to be the interaction between DMF and 
intracellular glutathione, leading to the inhibition of nuclear factor kappa B (NF-kB)-
mediated transcription of pro-inflammatory mediators and adhesion molecules. Other 
mechanisms of DMF are linked to impairing dendritic cell maturation, shifting cytokine 
production by T helper cells, and inducing apoptosis.[3] DMF is considered the most active 
FAE and thought to improve psoriasis via various immunomodulating, antiproliferative, 
and anti-angiogenic effects.[97-100] It is important to understand that DMF is a pro-drug. 
The metabolites monomethylfumarate (MMF) and S-(1,2-dimethoxycarbonylethyl) 
glutathione (GS-DMS) are the in vivo moieties; MMF is the bioactive metabolite.[101, 102] 
Furthermore, pharmacokinetic studies in psoriasis patients showed that, after the oral 
administration of FAE only MMF is detectable in serum.[103] In addition, a small random-
ized controlled trial among 45 psoriasis patients reported that the clinical efficacy of 
DMF alone is not significantly different from that of DMF with MEF.[104]
The long-term safety profile of FAE is favorable as an increased risk of infections and 
malignancies has not yet been described in patients treated continuously with FAE for 
more than 10 years.[105] Inconvenient adverse events such as gastrointestinal complaints 
and skin flushing occurring in the beginning of FAE treatment led to treatment discon-
tinuation in about 30 to 40% of patients. Several approaches have been undertaken 
or suggested to bypass this limiting factor for continuing FAE. First, a decrease of gas-
trointestinal complaints is achieved by using enteric-coated tablets. Second, fumarate 
formulations containing solely DMF, without MEF, may be associated with less adverse 
events.[106] Finally, slow-release formulations of FAE may further decrease the incidence 
of adverse events.[49] It is important to mention that that, since 2013, several cases of 
progressive multifocal leukoencephalopathy (PML) have been reported during treat-
ment with FAE.[107-116] However, the occurrence of PML as a result of therapy with FAE for 
the treatment of psoriasis is very rare, and extra vigilance is needed. 
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FUMARIC ACID AND FUMARIC ACID ESTERS
Fumaric acid is an organic dicarboxylic acid (C4H4O4); it occurs naturally in the me-
tabolism and plays a role in the tricarboxylic cycle (TCA cycle) and the carry-over of 
the amino-N from aspartate. Succinate (acetyl-CoA and oxaloacetate are synthesized 
to citrate, which is—through multiple steps—converted to succinate) is oxidized to 
fumarate. Succinate also enters the TCA-cycle as succinyl-CoA, a conversion product of 
the glucogenic amino acids methionine, isoleucine, and valine. The glucogenic amino 
acids phenylalanine and tyrosine enter the TCA cycle at the fumarate stage. Fumaric acid 
itself is poorly absorbed and has no therapeutic effect. Therefore, its esters are used for 
treatment. 
OFF-LABEL USE OF FAE
Although FAE formulations were initially developed for the systemic treatment of 
psoriasis, there are now an increasing number of reports of beneficial effects of FAE for 
several inflammatory and granulomatous skin diseases, such as cutaneous sarcoidosis, 
necrobiosis lipodica, granuloma annulare, and lichen planus.[118] However, FAE is not 
limited to the treatment of dermatological diseases. A DMF-formulation (BG-12) was 
effective in the treatment of multiple sclerosis in two phase 3 clinical trials.[119, 120] Since 
Summary of the effect of FAE in different cell types
Cell Type Cytokine/Signaling 
Effect
MMF/DMF Effect
T-cells IL-10↑, IL-5↑, MMF/DMF “TH1” “TH2” shift, HO-1↑ reduced CD4+, 
CD8+numbers
PBMC
CXCL8, 9, 10↓
TNF-α ↑, IL-10↑
IL-1RA↑
IL-4↑, IL-5↑
DMF Superoxide anions↑
B-cells NF- κB↓ n.d Bcl-2↓, induce apoptosis
Keratinocytes
IFNγ↓,IL-10↓,
IL-6↓, TGF-α↓,
CXCL8, 9, 10, 11↓
DMF HLA-DR↓,ICAM-1↓
Dendritic cells Il-12↓, MMF/DMF induce apoptosis, prevent cell differentiation
Endothelial cells prevent NF-κB 
translocation
DMF TNF α↓, ICAM-1↑, E-selectin↑ VCAM-1↑
Glia cells TNF-α↓, IL-1β↓, IL-6↓ DMF NQO-1↑,cellular Glutathion↑, NO↓
This table has been reproduced from Curr Neuropharmacol with permission from Bentham Science Publish-
ers.[117]
n.d = no data
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October 2014, BG-12 (Tecfidera®) has been registered for relapsing-remitting multiple 
sclerosis. Currently, FAE is being tested in pre-clinical studies for a variety of diseases.[121]
AIMS OF THIS THESIS
In an era of worldwide escalation of healthcare costs and the high expense of continu-
ous approval of new biologics, the scrutiny of biologics in fair comparison to more af-
fordable medications such as FAE is necessary. We need to recognize the life-long nature 
of psoriasis and the need for long-term maintenance therapy using systemic medication 
that is effective, safe, and affordable.
First, we investigated if FAE is an effective and safe treatment for psoriasis vulgaris. In 
our systematic review, we summarized and critically evaluated the current evidence of 
the efficacy, effectiveness, and safety of FAE in the treatment of psoriasis and concluded 
that FAE is considered suitable as a systemic treatment for moderate to severe plaque 
psoriasis (Chapter 2).
Thus, we first compared FAE to methotrexate, the past and present golden standard 
in the treatment of psoriasis (Chapter 3). With this study, we wanted to prove that FAE is 
as effective as the conventional systemic therapies for psoriasis. After concluding that 
FAE is as effective as methotrexate, we were interested in determining whether they are 
used as a popular psoriasis therapy in the Netherlands and how many Dutch dermatolo-
gists are using FAE for the treatment of their patients with psoriasis. (Chapter 4). The 
results indicated that FAE is a well-prescribed treatment for psoriasis in the Netherlands. 
Some reasons for patients’ discontinuation of this therapy included the common 
adverse events, such as diarrhea and flushing. In our view, these adverse events could 
be histamine induced. Therefore, we decided to investigate the use of antihistamines in 
the treatment with FAE to reduce adverse events (Chapter 5). Another reason why many 
patients discontinue their treatment with FAE in an early stage is the slow efficacy in the 
beginning of therapy due to the incremental dosage regimen. Thus, we thought that 
an alternative induction therapy with a combination of FAE and cyclosporine for ap-
proximately the first 12 weeks could offer a good solution for this obstacle (Chapter 6). 
In cases when cyclosporine does not show rapid efficacy or when a patient experiences 
contraindications to the use of cyclosporine, we looked for a legitimate alternative—a 
therapy similar to cyclosporine, only without the serious side effects such as nephro-
toxicity. Thus, we decided to investigate mycophenolate sodium (Myfortic®). Mycophe-
nolate mofetil (Cellcept®) has been shown to be effective in dealing with psoriasis, but 
Myfortic® has not previously been used for the treatment of psoriasis. Therefore, we 
investigated the efficacy and safety of this therapy for patients with moderate to severe 
psoriasis (Chapter 7). 
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BEFORE AND DURING TREATMENT:
– Objective assessment of the disease (BSA)
– Laboratory controls
– Set the expectations
– Education on the nature of AEs before starting treatment (e.g., types, severity (PML), 
frequency, transient nature)
– Positive encouragement; emphasizing product efficacy and the importance of stay-
ing on therapy
RECOMMENDED LABORATORY CONTROLS
Parameter Period in weeks
Pretreatment Month 1 Every 4 weeks until month 4 Thereafter
Liver enzymes X X X Every 8 weeks
Serum creatinine X X X Every 8 weeks
Urine status X X X Every 8 weeks
Pregnancy test X
Blood count* X X X Every 4 weeks
Not all tests may be necessary for all patients. Patient history, risk exposure and patient 
characteristics have to be taken into account. Further specific testing may be required 
according to clinical signs, risk and exposure.
*If leukocytes are <3000/μl, fumarate therapy needs to be stopped. If lymphocytes are 
<700/μl, patients should be kept on half of the last dose for 2–4 weeks and stopped 
if lymphocytes remain below 700/μl; if lymphocytes are <500/μl, treatment must be 
terminated.
This table was adapted from “European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 
2015 – Short version – EDF in cooperation with EADV and IPC” by A. Nast et al., 2015, J Eur Acad Dermatol Vene-
reol, Volume 29, p. 2277-2294. Copyright 2015 by John Wiley& Sons, Inc.. Adapted with permission.
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DOSING REGIMEN FOR MODERATE PLAQUE PSORIASIS
Week No. of tablets a day 30mg DMF No. of tablets a day 120mg DMF
Week 1 1
Week 2 2
Week 3 3
Week 4 1
Week 5 2
Week 6 3
Week 7 4
Week 8 5
Week 9 6
DOSING REGIMEN FOR SEVERE PLAQUE PSORIASIS (IN COMBINATION WITH 
CSA)
Week No. of tablets a day 120mg DMF mg/kg per day CsA
Week 1 1 5
Week 2 2 5
Week 3 3 5
Week 4 4 5
Week 5 5 5
Week 6 6 5*
From Week 12 decrease/increase to/with 1 or 2 
tablets gradually depending on 
PASI reduction
STOP
* Continue till 80% DMF dosage or week 12 depending on PASI reduction
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IN CASE OF ADVERSE EVENTS SUCH AS GASTROINTESTINAL COMPLAINTS 
AND FLUSHING
– Administration with food or milk
– Cetirizine 10 mg or Levocetirizine 5mg once or twice daily.
– Temporary dose reduction
IN CASE OF INTOLERABLE FLUSHING SYMPTOMS WITHOUT 
GASTROINTESTINAL COMPLAINTS
– Non enteric-coated aspirine (up to 325mg) 30 minutes prior to each DMF dose
Appendices
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Pros of FAE therapy for plaque psoriasis Cons of FAE therapy for plaque psoriasis
❏ Effective ❏ Unlicensed treatment
❏ Favorable risk/benefit profile ❏ Slow acting drug/long induction period
❏ Suitable as a first-line therapy ❏  Sometimes intolerable gastrointestinal adverse 
events
❏ Eligible for maintenance therapy ❏  Very rare risk of progressive multifocal 
leucoencephalopathy (PML)
❏ No drug interactions
❏  Suitable for combination therapy with other 
systemic therapies
❏ Easy oral administration
❏  Not time-consuming which results in better 
patient compliance
❏ Cost-effective compared to expensive biologics


 Chapter 2
Effi  cacy, eff ectiveness, and safety of 
fumaric acid esters in the treatment 
of psoriasis: a systematic review of 
randomized and observational studies
D.M.W. Balak
S. Fallah Arani
E. Hajdarbegovic
C.A.F. Hagemans
W.M. Bramer
H.B. Thio
H.A.M. Neumann
Chapter 2
42
ABSTRACT
Background: Fumaric acid esters (FAEs) are increasingly used as a systemic treatment 
for psoriasis, but there are still uncertainties on their suitability.
Objectives: to assess the evidence on efficacy and safety of FAEs in psoriasis treatment.
Methods: A systematic literature search in 7 databases up to August, 17th 2015. Inclu-
sion criteria were studies reporting clinical effects of FAEs in psoriasis patients without 
restrictions in study design, language, or publication date. Methodological quality of 
randomized controlled trials (RCTs) and level of quality were assessed using the Co-
chrane risk of bias tool and the Grades of Recommendation, Assessment, Development 
and Evaluation approach, respectively.
Results: Sixty-eight articles were included. There were 7 RCTs (total 449 patients) that 
had an unclear risk of bias and were too clinically heterogeneous to allow a meta-
analysis. Overall, mean psoriasis area and severity index decreased with 42-65% follow-
ing 12-16 weeks of treatment. There were 37 observational studies (total 3457 patients) 
that supported the RCT findings, but most were uncontrolled with a high risk of bias. 
Commonly reported adverse events were gastro-intestinal complaints and flushing 
complaints, leading to treatment withdrawal in 6-40%. Rare adverse events were renal 
Fanconi syndrome and progressive multifocal leukoencephalopathy. There was a lack of 
studies on long-term and comparisons to other treatments.
Conclusions: There is moderate-quality evidence to recommend the use of oral FAEs as 
treatment for plaque psoriasis in adult patients. Studies focusing on long-term safety 
and comparison to systemic psoriasis treatments could lead to a better positioning of 
FAEs as psoriasis treatment.
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INTRODUCTION  
Fumaric acid esters (FAEs) are small molecules that have immunomodulating properties.1 
Oral FAEs have been used to treat  psoriasis for 5 decades. There is a long- standing tradi-
tion in Germany and the Netherlands to treat psoriasis patients with FAEs as a first-line 
systemic treatment.2,3 In other countries such as the U.K., FAEs are increasingly reported 
as treatment for psoriasis.4,5 Globally, FAEs are limited in   availability and unlicensed 
for the treatment of psoriasis, primarily due to a lack of a high-quality evidence-based 
development with well-performed randomized controlled trials. The development of 
FAEs was mostly done empirical. 
FAEs were introduced in 1959 as potential anti-psoriatic drugs by the German chemist 
Schweckendiek, who in several self-experiments reported improvement of psoriasis 
using different FAEs.6 In the following two decades, FAEs were empirically developed 
further with favourable treatment effects.7-10 However, initial dermatology- based obser-
vations on FAEs treatment showed variable improvements and concerns on safety.11-13 
Hence, for a long time FAEs were regarded as a controversial psoriasis treatment.14 
In the mid-1980s, there was a revival of interest in FAEs as potential psoriasis drug, 
which was partly driven by requests from patients associations.15-17 The first random-
ized, double-blind, placebo-controlled trials were published in the early 1990s.18,19 
Subsequently, FAEs became approved by German regulatory agencies in 1994 for the 
treatment of severe psoriasis and in 2011 for moderate psoriasis. The licensed FAE-for-
mulation (Fumaderm) is a mixture of dimethylfumarate (DMF) and lesser concentrations 
of monoethylfumarate (MEF)-salts.20 
The mechanisms of action of FAEs are not completely understood. DMF is considered 
the most active FAE and thought to improve psoriasis via various immunomodulating, 
antiproliferative, and anti-angiogenic effects.21-24 Of importance, DMF is a pro-drug. The 
metabolites monomethylfumarate (MMF) and S-(1,2- dimethoxycarbonylethyl)glutathi-
one (GS-DMS) are the in vivo moieties; MMF is the bioactive metabolite.25,26 
Currently, FAEs are one of the most commonly prescribed treatments for psoriasis 
in Germany.27 In other European countries, such as the Netherlands and the U.K, FAEs 
are increasingly in use for psoriasis treatment albeit as a unlicensed drug. In the U.K., 
FAEs are considered a second-line systemic therapy for psoriasis.28 The 2009 European 
S3-guidelines recommended FAEs as systemic treatment for plaque psoriasis, but no 
consensus was reached for a recommendation as a maintenance treatment.29 In the 
2015 update of the European S3-guidelines, FAEs are recommended for the long-term 
treatment of psoriasis, but the recommendation is based on expert opinion only.30 
Hence, there are uncertainties on the suitability of FAEs as a psoriasis treatment. 
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In this systematic review, we aimed to comprehensively summarize and critically ap-
praise the evidence on the efficacy, effectiveness, and safety of oral FAEs treatment in 
patients with psoriasis. 
METHODS 
Literature search strategy 
The databases Embase.com, Medline (Ovid), Cochrane central registry of trials (CEN-
TRAL), Web-of-Science, Scopus, PubMed (the subset as supplied by publisher, contain-
ing non-indexed citations), and Google scholar were searched from inception to August, 
17th 2015. The searches, conducted by an experienced biomedical information special-
ist (WB), combined multiple thesaurus terms and words in title/abstract for FAEs with 
terms for psoriasis. Details of the search strategy are summarized in Appendix 1. 
Selection criteria 
Articles were screened for relevance according to the title and abstract. Remaining ar-
ticles were assessed full text. Eligible for inclusion were articles describing clinical effects 
(i.e. efficacy, effectiveness, and/or safety outcomes) of oral FAEs in psoriasis treatment. 
To obtain a complete overview as much as possible, we did not apply restrictions for 
publication date, study design, or publication language. 
Data extraction 
Using a pre-defined data form, we extracted data on study design, study setting, sample 
size, study analyses, FAE formulation and dosage, efficacy or effectiveness outcomes, 
and safety outcomes. 
Quality assessment 
The methodological quality of RCTs and observational studies was assessed using the 
Cochrane risk of bias tool and the risk of bias assessment tool for nonrandomized studies 
(RoBANS), respectively.31,32 Overall level of quality of evidence was assessed according 
to the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) 
approach.33 
Outcomes and data analysis 
We aimed to compare treatment effects of FAEs versus placebo, FAEs versus other 
systemic treatments, different FAEs formulations, and different FAEs dosage levels. In 
addition, we looked at treatment effects of FAEs in combination with other psoriasis 
treatments. 
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The efficacy and effectiveness outcomes of interest were changes in psoriasis disease 
activity as measured by psoriasis area and severity index (PASI), body surface affected 
(BSA), or global psoriasis assessments. Additional outcomes included changes in arthri-
tis, nail symptoms, and health-related quality of life. 
The safety outcomes included proportions of patients reported with serious adverse 
events, subjective adverse events, laboratory abnormalities, and adverse events requir-
ing withdrawal of treatment. 
We classified observational studies that assessed FAEs treatment 12 months or longer 
into long-term studies. 
Two researchers (DB and CH) independently assessed articles for eligibility for inclu-
sion, extracted data, and evaluated methodological quality. Any disagreements were 
resolved by consensus. 
Descriptive statistics were used to analyse data. Reporting of findings was in line 
with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines.34 A pre-defined review protocol was used, but not registered beforehand. 
RESULTS 
Literature search 
The literature search yielded 2515 hits, of which 275 articles were assessed full-text. 
Sixty-eight articles were included (See Figure 1). 
RCTs on FAEs treatment for psoriasis 
Characteristics of RCTs 
There were 7 RCTs found, published in the period 1990-2014.18,19,35-38 Of these, three 
trials compared FAEs to placebo, one trial compared two different FAEs-formulations to 
placebo, one trial compared FAEs to methotrexate, one trial compared the combination 
of FAEs with topical calcipotriol to FAEs monotherapy, and the most recent trial com-
pared FAEs plus an oral histamine antagonist to FAEs monotherapy. Two RCTs from the 
Netherlands were published additionally in an extended version in a Dutch journal.39,40 
The characteristics of study design and study population of each RCT are summarized 
in Table 1. 
The sample sizes of the RCTs were relatively small, ranging from 27 to 134 patients. 
Overall, 449 patients were included. The majority of the RCTs included patients with 
chronic plaque psoriasis. One RCT enrolled patients with psoriatic arthritis.41 All included 
patients were aged 18 years or older. There was considerable clinical heterogeneity 
among the RCTs in the efficacy outcomes, time of efficacy assessment, and used FAE 
formulations. Frequently used efficacy outcomes were changes in PASI or in BSA. The 
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treatment duration was relatively short, ranging from 2.8 to 4 months. There were 
differences in the evaluated FAEs-formulations. Most RCT’s applied the standardized 
incremental dosage regimen up to FAEs 215 mg six times a day (equals 720 mg DMF). 
The study of Nieboer18 used a different dosage regimen up to FAEs 215 mg four times a 
day (equals 480 mg DMF). 
Methodological quality assessment of RCTs 
Assessment of the methodological quality of the RCTs using the Cochrane risk of bias 
tool yielded an unclear risk of bias, often due to insufficient reporting. The overall level 
of quality of the included RCTs in the GRADE approach was therefore downgraded to 
moderate. 
TABLES AND FIGURES 
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Figure 1: Overview of literature search and selection
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Efficacy outcomes reported in RCTs 
Due to significant clinical heterogeneity and the small number of RCTs available (n = 7), 
we decided not to pool the efficacy data in a meta-analysis. All RCTs reported statistically 
significant efficacy results for FAEs. Overall, mean PASI decreased with 42- 65% following 
12-16 weeks of treatment. The efficacy results are summarized in Table 1. 
All placebo-controlled RCTs reported statistically significant improvement in psoria-
sis severity by FAEs compared to placebo.19,35 The placebo-controlled RCT in psoriatic 
arthritis found significant improvement in skin lesions, but only modest improvement 
in arthritis.41 Only one RCT reported improvements in health-related quality of life fol-
lowing FAEs-treatment.38 
The only head-to-head RCT compared FAEs to methotrexate and reported similar 
efficacy results following 16 weeks of treatment.36 A RCT directly comparing a FAEs-
formulation containing DMF and MEF to a DMF-formulation reported equal short- term 
efficacy.18 
Addition of a topical vitamin D analogue calcipotriol resulted in greater and faster 
improvement of psoriasis severity compared to FAEs-treatment alone.37 In contrast, ad-
dition of an oral histamine-1 receptor antagonist cetirizine did not increase the efficacy 
of FAEs.38 
Safety outcomes in RCTs 
FAEs treatment was not associated with an increased risk of serious or severe adverse 
events. There was only one serious adverse event reported: adnexitis in a subject that 
received FAEs and calcipotriol, which was rated as unlikely related to study medication.37 
The proportion of patients with AEs was relatively high, ranging from 69% to 92% (See 
Table 1). The most commonly reported AEs were gastrointestinal complaints (up to 
100%) and flushing (up to 92%) Common reported laboratory abnormalities included 
elevated liver enzymes (up to 62%), eosinophilia (up to 46%), and lymphocytopenia (up 
to 38%), but rarely resulted in treatment discontinuation. Definitions and grading of 
laboratory abnormalities were not reported in the individual studies. There was one case 
of reversible renal insufficiency reported.39 Eight to 39% of patients discontinued FAEs 
treatment due to adverse events, mostly due to intolerable gastrointestinal or flushing 
complaints. 
Observational studies on FAEs treatment for psoriasis 
Characteristics of observational studies 
There were 37 observational studies included from the period 1987-2015 with a total 
of 3457 patients. There was considerable clinical heterogeneity in FAEs formulations 
and treatment duration. The characteristics of the included observational studies are 
summarized in Table 2 The majority (73%) of these studies were open-label, single-
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center, cohort studies that were often uncontrolled. There were 2 cross-sectional studies 
42,43 , the rest of the observational studies were case series (n=8). The majority of studies 
included patients with moderate to severe plaque psoriasis. Two studies evaluated 
FAEs in mild cases of plaque psoriasis. In some studies small number of patients with 
subtypes other than plaque psoriasis were included, such as guttate or palmoplantar 
pustular psoriasis. Almost all studies involved adult patients, except for 2 studies that 
included paediatric psoriasis patients.44,45 Sample sizes ranged from 6 to 984. The treat-
ment duration ranged from 1 month to 14 years. There were 18 studies which described 
long-term FAEs treatment from 1 year up to 14 years. Most studies assessed Fumaderm 
with the recommended dosage schedule. There was variation in the used effectiveness 
outcomes. PASI, PGA, and global psoriasis severity assessments were used. 
Quality assessment of observational studies 
Most of the observational studies were retrospective and uncontrolled single-center 
studies with a high or unclear risk of bias. Following the GRADE approach, there were 
insufficient grounds to upgrade the quality of evidence. Hence, the overall level of qual-
ity using GRADE was evaluated as a very low quality of evidence. 
Effectiveness in observational studies 
The effectiveness data are summarized in Table 2 There was a wide range in reported 
effectiveness outcomes. Overall, mean reductions in PASI ranged from 13% to 86% fol-
lowing 3-4 months of treatment. Reported PASI-75 responses ranged from 8% to 33%. 
One retrospective, single-center cohort study reported a drug survival of FAEs of 60% 
after 4 years of treatment.46 Several studies reported improvements in patient-reported 
quality of life.47-49 There were anecdotal data on combination treatment with other 
systemic treatments.50,51 One registry-study from Austria found similar effectiveness of 
FAEs and methotrexate.52 
Two small retrospective case series from the Netherlands and Germany assessed the 
effects of FAEs in children with psoriasis.44,45 The effectiveness results of FAEs were in line 
with results reported in adult patients. 
Safety outcomes in observational studies 
No deaths or serious adverse events were reported in the observational studies. The 
adverse events profile was in general similar among the studies. The most commonly 
reported adverse events were gastrointestinal complaints and flushing (See Table 3). 
Commonly reported laboratory abnormalities included lymphocytopenia, elevated liver 
enzymes, and eosinophilia. 
Forty-five to 87% of patients had experienced an adverse event. The proportion of 
patients discontinuing FAEs treatment due to adverse events ranged from 6% to 47%. 
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Fumarates for psoriasis: a systematic review 
The most common cause for early treatment discontinuation was intolerable gastroin-
testinal symptoms and, to a lesser extent, severe flushing symptoms. There were few 
reported treatment discontinuations due to laboratory abnormalities. 
There were few studies that specifically evaluated long-term treatment with FAEs. The 
available data indicated no increased risk for infections, malignancies, or other serious 
adverse events associated with long-term FAE treatment. In a small, retrospective single 
Table 3: Adverse events associated with FAEs in psoriasis treatment reported in ≤ 5 patients in randomized 
and observational studies
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/bjd.14500 
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Table 3: Adverse events associated with FAEs in psoriasis treatment reported in   5 patients in 
randomized and ob ervational studies 
Adverse event Combined total 
number of patients 
Lymphocytopenia* 1115
Gastrointestinal complaints 670
Flushing 626
Increase in liver enzymes* 341
Eosinophilia* 254
Proteinuria* 242
Leukocytopenia* 218
Increase in creatinine* 79
Pruritus 55
Fatigue 55
Headache 34
Malaise 33
Increase in urea* 19
Dizziness 15
Increase in cholesterol* 12
Hypertension 10
Dermatitis/rash 9
Hyperkalaemia* 8
Chapter 2
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center study among patients treated with FAE continuously for up to 10 to 14 years, 
no serious adverse events or malignancies were observed.53 Similar safety results were 
reported in a large, German study among nearly 1000 patients treated with FAE for a 
mean duration of 3.5 years.42 
Case reports on adverse events of FAEs 
Twenty-four case reports described adverse events associated with FAEs treatment 
(See Table 6). Of these, several involved immunosuppressive events linked to FAEs- 
induced lymphocytopenia: Kaposi sarcoma54, organizing pneumonia55, tuberculous 
lymphadenitis56, squamous cell carcinoma57, melanoma58, and progressive multifocal 
leukoencephalopathy (PML).59-65 There have been 7 cases published of PML. In most 
cases the development of PML was linked to exposure to severe low lymphocyte counts 
for prolonged periods of time. However, there was one case of PML linked to moderate 
lymphocytopenia.65 
Furthermore, there were several renal adverse events reported: six cases of a drug-
induced Fanconi syndrome linked to FAEs.66-71 Fanconi syndrome is characterized by 
proximal renal tubular dysfunction and can lead to proteinuria, glycosuria, and low 
serum levels of phosphate. Furthermore, there were 9 cases of acute renal insufficiency 
linked to FAEs. These cases of acute renal insufficiency were all reported in the 1990s and 
involved uncontrolled use of oral and topical FAEs. 
Lastly, there was one case reported of collagenous colitis during FAEs treatment, 
which may be associated with a FAE-induced T helper 2 immune response.72 
DISCUSSION 
FAEs have a long history as a systemic psoriasis treatment, but their development was 
not based on high-quality evidence. Here, we assessed studies on efficacy and safety of 
FAEs in psoriasis treatment. The available evidence was limited with 7 RCTs with rela-
tively small sample sizes and an unclear risk of bias. Overall, mean PASI decreased with 
42-65% following 12-16 weeks of treatment. The number of observational studies (n=37) 
was much larger, but the majority were uncontrolled and with a high risk of bias. The 
safety profile of FAEs was well-characterized. Intolerable gastrointestinal complaints and 
flushing led to early treatment withdrawal in 6-40%. Lymphocytopenia, eosinophilia, 
increased liver enzymes, and proteinuria were commonly observed, but rarely resulted 
in FAEs discontinuation. Studies with long-term data were lacking. 
To appreciate our results, several aspects of this systematic review need to be consid-
ered. Strengths of our study include the extensive literature search involving multiple 
bibliographic databases and the fact that we did not exclude specific study types or 
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publication dates, making this the largest systematic review on FAEs in psoriasis to 
date. In addition, we included articles written in languages other than English, thereby 
decreasing language bias. Furthermore, quality of the included studies was critically 
evaluated using the GRADE approach. A limitation was that most included studies were 
open-label and uncontrolled studies with a low level of evidence. Moreover, due to 
considerable clinical heterogeneity among the studies, a meta- analysis was not pos-
sible. Furthermore, the majority of the RCTs from the 1990s did not adhere to reporting 
guidelines that are now considered standard (e.g. CONSORT guidelines).73 Moreover, 
there was a lack of standardization of efficacy outcomes across the RCTs. 
A recent Cochrane review of the effects of FAEs in psoriasis could not perform a meta-
analysis because of incomplete and heterogeneous reporting of outcomes.74 Several 
previous studies did apply a meta-analysis on a limited number of studies. These meta-
analyses reported similar efficacy of FAEs to methotrexate75, superior 
efficacy of FAEs compared to the biologic efalizumab76, and significant differences of 
FAEs compared to placebo.77 
Most studies assessed the FAE-formulation Fumaderm that has had German market-
ing authorisation since 1994. The choice of the components of Fumaderm (i.e. DMF 
and MEF-salts) was not based on rational pharmacological studies. Recent preclinical 
studies suggest that DMF is the most active FAEs with anti-psoriatic effects.78,79 In 
particular, DMF is a pro-drug for which MMF is the bioactive metabolite.20 Two small 
studies from the 1990s compared a FAEs-formulation containing DMF plus MEF to a 
DMF-formulation and found no statistically significant differences.18,80 However, these 
studies applied different dosage schedules and did not use validated efficacy outcomes. 
Consequently, clear conclusions cannot be made on the results of these results. A novel 
DMF-formulation BG-12 was assessed in several psoriasis RCTs81, but these studies have 
yet to be published. The BG12-formulation later became approved for treatment of 
multiple sclerosis by the FDA in 2013.82,83 Several novel FAEs-formulations are now in 
development, e.g. a MMF-linker formulation and a DMF- formulation (Clinicaltrials.gov, 
numbers NCT02173301 and NCT01230138, respectively). 
Since the mid-1990s, FAEs are increasingly being used and regarded as a systemic 
treatment with a favorable risk-benefit ratio. FAEs have several advantages. FAEs seem 
suitable for psoriasis patients with comorbidity. Also, there are no known drug-inter-
actions. Also, FAEs appear to have no increased risk of significant immunosuppressive 
adverse events, in contrast to other systemic classical treatments.84 Although lympho-
cytopenia is relatively frequently observed during FAEs treatment in about 50% of 
patients, in most cases the lymphocyte reductions are mild.30 A small proportion of pa-
tients of circa 3% has a severe lymphocytopenia during FAEs treatment.30 FAEs-induced 
lymphocytopenia does not seem to cause significant immunosuppression as long as 
lymphocyte-counts are closely monitored according to the guidelines.85 FAE dosage 
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reduction is recommended in case of lymphocyte-counts below 700 per cubic mm and 
direct FAE discontinuation is recommended in case of lymphocyte-counts below 500 
per cubic mm.29,30 The occurrence of opportunistic infections during FAEs treatment was 
linked to exposure to prolonged severe lymphocytopenia or to other known risk factors. 
It is noted that the experience of FAEs as psoriasis treatment is larger than the published 
data.86 It is interesting to compare the level of evidence of FAEs to that of methotrexate. 
Methotrexate is globally the most commonly used classical systemic treatment for pso-
riasis.87 The available evidence, however, is limited even though methotrexate is in use 
since 1958.29 Results from a RCT and a registry-based observational study indicated that 
methotrexate and FAEs have similar clinical improvements in short-term treatment.36,52 
Excluding methotrexate, FAEs have not been compared head-to-head to other systemic 
psoriasis treatments. Such comparative studies are needed to better define the position 
of FAEs as psoriasis treatment.4 
In conclusion, FAEs are considered to be suitable as a systemic treatment for moderate 
to severe plaque psoriasis, but the quality of the available evidence is low. Future stud-
ies could focus to optimize FAEs-formulations and to compare FAEs to other systemic 
treatments in order to better define the position of FAEs in the landscape of psoriasis 
treatment. 
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ABSTRACT
Background: Methotrexate and fumarates are effective systemic therapies for mod-
erate to severe psoriasis according to the European S3-guidelines. We conducted a 
randomised, controlled trial comparing the effectiveness and the adverse events of 
methotrexate and fumarates.
Methods: A total of 60 patients with moderate to severe psoriasis vulgaris were ran-
domly assigned to treatment for 16 weeks with either methotrexate (30 patients; 15 mg 
per week) or fumarates (30 patients; 30 mg, followed by 120 mg orally according to a 
standard progressive dosage regimen) and were followed-up for 4 weeks. The primary 
endpoint with respect to the efficacy was the difference in mean change from baseline 
in PASI after 12 weeks of treatment.. The study was powered to detect a difference of 5 
points. Analyses were by intention to treat. This study was registered with trialregister.
nl, number ISRCTN76608307.
Results: Six patients were excluded because five were not eligible and one withdrew 
the informed consent. Two patients in the methotrexate group and one in the fumarate 
group dropped-out during the 12 weeks of treatment because of non-appearance at the 
outpatient clinic. A total of 25 patients in the methotrexate group and 26 in the fumarate 
group were evaluated in the primary analysis. After 12 weeks of treatment, the mean 
(±SD) PASI decreased from 14.5±3.0 at baseline to 6.7±4.5 in the 25 patients treated with 
methotrexate, whereas it decreased from 18.1±7 to 10.5±6.7 in the 26 patients treated 
with fumarates. After adjustment for baseline values, the absolute difference (fumarates 
minus methotrexate) in the mean values at 12 weeks was 1.4 (95 percent confidence 
interval, –2.0 to 4.7; P=0.417).
Conclusion: In this randomised trial methotrexate and fumarates were found to be 
equally effective in the treatment of patients with moderate to severe psoriasis. No seri-
ous or irreversible adverse events were observed in any of the patients.
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INTRODUCTION
Psoriasis is a chronic, immune-mediated, inflammatory skin disease with the prevalence 
of 2-3% in the worldwide Caucasian population. 1,2 Systemic therapy with methotrexate 
is known to be effective in the treatment of severe psoriasis.3 Like other currently used 
systemic treatments for the long-term therapy of psoriasis, methotrexate is hampered 
by its cumulative adverse events, especially hepatotoxicity. Recently, the Dutch public 
health authority issued a warning to medical professionals, particularly oncologists, 
rheumatologists and dermatologists on the use of methotrexate and its fatal adverse 
events generally through prescription errors, overdoses and lack of monitoring.4
Fumarate therapy, an oral mixture of dimethylfumarate and salts of monomethylfu-
marate was designed in 1959 by the German chemist Walter Schweckendiek. Fumarate 
therapy is only registered in Germany and has proven to be a safe and effective systemic 
treatment for psoriasis vulgaris over the years.5,6 The mode of action of fumarates is 
thought to be via an anti-proliferative effect on keratinocytes and modulation of T-cell 
activity partly via the induction of preferential apoptosis of activated T cells .7
To date no head-to-head randomised clinical trials with fumarate therapy and other 
systemic therapies for psoriasis have been reported. Comparing fumarates with metho-
trexate may provide us with important information on the differences between these 
therapies, which may be of great help for the safety and the overall quality of life of 
patients with psoriasis. Moreover, in this era of biologicals costs play an important role 
in the decision making with regard to therapy in psoriasis. At present, methotrexate and 
fumarates are by far the cheapest systemic therapies for psoriasis.
We compared the clinical outcome and the adverse events profile in patients with 
moderate to severe psoriasis vulgaris (en plaque) who were either treated with metho-
trexate or fumerates in a multi-centre, prospective, randomised controlled clinical trial. 
We investigated the difference in the means between the PASI after 12 weeks of treat-
ment to determine the efficacy. Adverse events in all the patients were also recorded.
METHODS
Patients
Patients with moderate to severe psoriasis were recruited between October 2006 and 
February 2009 from the Departments of Dermatology at the Erasmus MC, Rotterdam 
and from the Catharina Hospital, Eindhoven. Eligible patients were at least 18 years old 
suffering from chronic plaque-type psoriasis with a psoriasis area-and-severity index 
(PASI) of at least 10. The PASI combines assessments of psoriasis-induced erythema, 
scaling and skin thickness each weighted according to the size of the affected area. All 
Chapter 3
68
the patients provided signed informed consent. The study was approved by the medical 
ethics committees at both the institutions.
The exclusion criteria were: (1) patients with other clinical forms of psoriasis like pso-
riasis guttata or pustulosa; (2) patients in need of co-medications that may interfere with 
the psoriasis; (3) patients with toxicity for either fumarates or methotrexate; (4) acute in-
fections requiring antimicrobial therapy; (5) patients with hepatitis B, C, HIV, pregnancy 
and breast-feeding; (6) patients who desired to have children within 3 months after the 
cessation of the therapy and non-compliant contraception; (7) patients with relevant 
cardiovascular, pulmonary, cerebral, neurological, renal and haematological diseases; 
(8) patients with diabetes mellitus (insulin-dependent); (9) patients with high risk of liver 
function disturbances and drug or alcohol abuse.
Laboratory investigations
Laboratory tests were performed in all eligible patients. The following haematological 
values were determined: haemoglobin, haematocrit, red blood cell count, total white 
cell count, leukocyte differential counts and platelet count. Blood chemistry analyses 
consisted of determining the levels of the following: sodium, potassium, calcium, 
inorganic phosphate, total protein, albumin, glucose, total cholesterol, triglycerides, 
blood urea (BUN), creatinine, uric acid, total bilirubin, alkaline phosphate, aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase 
(gamma-GT), creatinine kinase and lactate dehydrogenase (LDH).
Patients who were treated with fumarates underwent laboratory tests and urine 
analyses at the screenings visit followed by every 4 weeks (4, 8, 12, 16, 20) and patients 
who were treated with methotrexate underwent the same laboratory tests and urine 
analyses on day 3, in weeks 1, 2, 4, 12, 16 and 20.
Study design
All eligible patients were randomly assigned on a 1:1 basis to receive 16 weeks of treat-
ment with either fumarates or methotrexate after all entry criteria had been met and 
informed consent had been obtained. Randomisation could not be blinded because 
treatment intake differed in both groups. Randomisation was performed centrally 
according to a computer-generated randomisation list. Only the research-nurse, who 
had no contact with the patients before randomisation had insight into the allocation 
schedule.
Study endpoint
The primary endpoint with respect to the efficacy was the difference in the mean change 
from the baseline iPASI after 12 weeks of treatment. The screening period, during which 
no active treatment for psoriasis was allowed, lasted two weeks in patients who had 
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received topical therapies and four weeks for those who had received UVB-light therapy, 
PUVA photo-chemotherapy, or systemic drugs (‘wash out period’). Patients on fumarate 
therapy returned for clinical evaluation (including physical examination, vital signs, con-
comitant medications, monitoring for adverse events and evaluation of psoriasis activity 
(PASI) and photographs) every 4 weeks (weeks 4, 8, 12, 16) and patients on methotrexate 
therapy in weeks 1, 2, 4, 12, 16. The treatment was stopped after 16 weeks and all the 
patients were followed-up for another 4 weeks.
Treatment regimens
Patients received 30 mg and 120 mg fumerates orally according to a standard progres-
sive dosage regimen. After week 9, the therapy was continued at the maximum dose 
of 720 mg of fumarate.8 We used fumarates consisting of dimethylfumarate and salts 
of monoethylfumarate (Magistrale Bereider Oud-Beijerland, Oud-Beijerland, the Neth-
erlands). The methotrexate group started with an initial dose of 5 mg per week with 
laboratory controls after 3 days and 1 week. Thereafter the dose was gradually increased 
up to 15 mg per week orally according to the Weinstein scheme as 15 mg/week in three 
equal doses of 5 mg each 12 hours apart. The dose was tapered to 12.5 mg/week at week 
13, 10 mg/week at week 14, 5 mg/week at week 15 and 2.5 mg/week at week 16. After 
16 weeks the medication was stopped. During the systemic treatment and the follow-
up period, no concomitant anti-psoriatic therapy was permitted, with the exception of 
emollients. Drugs known to interfere with psoriasis or with the systemic treatments (or 
with both) were not allowed.
OUTCOMES
Clinical efficacy
The PASI was the primary outcome measure and was determined at the baseline and at 
week 4, 12, 16 and 20 in the fumarate group and the methotrexate group by the same 
trained assessors (one trained physician and a research-nurse in consensus at each site).
Adverse events
We evaluated adverse events known to be associated with methotrexate or fumarates 
and those that the patient deemed to be relevant to the treatment. Patients had to keep 
a diary on all adverse events and necessary co-medications. Adverse events that did 
not require additional medications or discontinuation of the study medication were 
classified as mild.
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Statistical analysis
Comparison of baseline PASI was done using the Mann-Whitney test and the chi-square 
test for continuous and categorical variables, respectively. Mean changes in the PASI af-
ter the start of the treatment were evaluated using repeated measurements Anova (SAS 
PROC MIXED using an unstructured covariance matrix SAS version 9.2 (SAS Institute Inc., 
Cary, NC, USA). Time (week of treatment) was included in this analysis as a fixed factor 
and the baseline PASI was used as a covariate.
When designing this trial, we calculated that 25 patients in each group were needed in 
this trial to have a 90% power to detect a difference of 5 points in the mean PASI after 12 
weeks of treatment, assuming a SD of 5.3. Sixty patients were randomised (30 patients in 
each group) to allow for any eventual drop-outs. Analysis was by intention-to-treat and 
two-sided P-values of 0.05 were considered to indicate statistical significance.
RESULTS
Patients
Baseline demographics and clinical characteristics are summarised in Table 1. Between 
October 2006 and February 2009, 72 patients with moderate to severe psoriasis were 
screened, 60 of whom were randomized (Fig. 1). Six patients (3 in the methotrexate and 
3 in the fumarate group) were subsequently excluded because 5 were not eligible and 
one withdrew informed consent. Two patients in the methotrexate group and 1 patient 
in the fumarate group dropped-out during the first 12 weeks of treatment because of 
non-appearance at the outpatient clinic (1 patient stopped visiting the outpatient clinic 
in week 4 and 2 patients in week 6). A total of 25 patients in the methotrexate group 
and 26 patients in the fumarate group were evaluated for the primary endpoint PASI at 
week 12.
After 12 weeks of treatment, the mean (+/- SD) PASI decreased from 14.5 ± 3.0 at the 
baseline to 6.7 ± 4.5 in the 25 patients in the methotrexate group, whereas it decreased 
from 18.1±7.0 to 10.5 ± 6.7 in the 26 patients in the fumarate group. After adjustment 
for the baseline PASI, the absolute difference (fumarates minus methotrexate) in mean 
values at 12 weeks was 1.4 (95 percent confidence interval, –2.0 to 4.7; P=0.417) (Fig. 2). 
At week 4 the baseline adjusted difference was 4.1 (95% CI: 1.9 to 6.3; P=0.001).
Eleven (42%) of the 26 evaluated patients in the fumarate group and 15 (60%) of 25 
evaluated patients in the methotrexate group had a 50% reduction in the PASI (P=0.325) 
after 12 weeks of treatment (Figure 2). Partial remission (defined as a reduction of more 
than 75% in the baseline PASI) was achieved in 5 (19%) of the 26 evaluated patients 
in the fumarate group and 6 (24%) of the 25 evaluated patients in the methotrexate 
group after 12 weeks of treatment (P=0.941). An almost complete remission (defined 
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as a reduction of more than 90% in the baseline PASI) during the 12 weeks of treatment 
was noted in 1 (4%) of the 26 evaluated patients in the fumarate group and 2 (8%) of the 
25 evaluated patients in the methotrexate group (P=0.610).
We found no significant differences in the percentages of patients with partial remis-
sion (PASI ≥ 75% decrease, both P ≥ 0.65) and almost complete remission (PASI ≥ 90%, P 
≥ 0.96) after oral treatment was stopped in week 16.
	  
Figure 1. Enrollment, Randomization, and Treatment through week 20.
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In week 20, 13 (72%) of the 18 evaluated patients in the fumarate group and 10 (53%) 
of the 19 evaluated patients in the methotrexate group had a 50% reduction in the PASI 
(P=0.374), 7 (39%) of the18 evaluated patients in the fumarate group and 6 (32%) of 
the19 evaluated patients in the methotrexate group had a 75% reduction in the PASI 
(P=0.642). One (6%) of the 18 evaluated patients in the fumarate group and 2 (11%) of 
the 19 evaluated patients in the methotrexate group achieved a 90% reduction in the 
PASI (P=1.00). Three patients in the methotrexate group showed a worsening in the PASI 
as compared with the baseline PASI (with the highest worsening of the PASI from 11.7 to 
14.8) in week 20 as compared with no patients in the fumarate group.
Adverse events
The total number of reported adverse events was 60 in the fumarate group and 78 in 
the methotrexate group. Adverse events were reported by 24 patients in the fumarate 
group and 27 patients in the methotrexate group (P=0.236). Signifi cantly more patients 
reported fl ushing (13 in the fumarate group and 2 in the methotrexate group, P=0.002) 
and fl u-like symptoms (1 in the fumarate group and 7 in the methotrexate group, 
P=0.050). Additional medication to relieve adverse events was not necessary in either 
group.
Overall, the tolerability of both drugs was good. Two (8%) of the 26 patients in the 
fumarate group had to discontinue treatment because of diarrhoea, worsening of the 
psoriasis and itch. Four (16%) of the 25 patients in the methotrexate group had to stop 
Table 1 Demographic and clinical characteristics of included patients
Characteristic Methotrexate	  	  (n=27)	   Fumarates	  (n=27)
Age	  (years),	  mean	  ±	  SD 41±14 43±16
Sex,	  n	  (%)
Male 16	  (59) 20	  (74)
Female 11	  (41) 7	  (26)
Weight	  (kg),	  mean	  ±	  SD 83±	  17 87±21
Duration	  psoriasis	  in	  years 17±14 16±9
Previous	  treatment,	  n	  (%) 26	  (96) 24	  (89)
Topical	  agent	  a 26	  (96) 24	  (89)
Phototherapy	  b 13	  (48) 16	  (59)
Conventional	  systemic	  agents	  c 16	  (59) 17	  (63)
Biological	  agents	  d 2	  (7) 2	  (7)
Baseline	  PASI-­‐score,	  mean	  ±	  SD 14.7±3.0 18.0±6.9
a	  Patients	  had	  to	  have	  discontinued	  topical	  therapies	  (except	  moisturizers	  and	  shampoos)
2	  weeks,	  conventional	  systemic	  therapies	  and	  	  biological	  agents	  4	  weeks	  before	  randomization.
b	  Includes	  ultraviolet	  B	  light	  and	  psoralen	  plus	  ultraviolet	  A.	  c	  Includes	  psoralen	  plus	  ultraviolet	  A,	  
fumarates,	  methotrexate,	  acitretin,	  and	  cyclosporin.	  d	  Includes	  etanercept,	  efalizumab,
	  infliximab,	  and	  adalimumab.	  PASI,	  Psoriasis	  Area	  and	  Severity	  Index	  (scale	  0	  -­‐	  72)
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Fig 2. a) Clinical response to treatment expressed as the change from baseline of the Psoriasis Area-and-
Severity Index (PASI)-score over time. FUM=fumarates group, MTX=methotrexate group. Meanchanges 
(±SE) of the PASI-scores during the treatment and the follow-up. The mean values of PASI, with SE between 
parentheses, at the various time points are shown at the bottom. b) The proportions of patients randomly 
assigned to receive either fumarates or methotrexate till week 20 at each time point, according to variable 
degrees of improvement (50%, 75%, 90%) in the PASI-score.
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treatment, two because of elevations in their liver enzymes and one because of recurrent 
angina. The elevations in the liver enzymes were mild and all values returned to normal 
within four to eight weeks after stopping the treatment. Elevations in liver enzymes dur-
ing methotrexate treatment have been well documented. Whether the hepatotoxicity 
of methotrexate is reduced by folic acid supplement is not clearly understood. However, 
since folic acid has no known serious adverse events and is cheap, it was prescribed 
to our patients. No serious or irreversible adverse events were observed in any of the 
participating patients.
Laboratory investigations
Treatment had to be discontinued in four (15%) of the 27 patients in the methotrexate 
group because of elevated liver enzyme levels of 200-300% of the values at the screen-
ing visit (the highest measured values were AST 66 U L-1, ALT 140 U L-1, LDH 290 U L-1). 
These laboratory abnormalities were transient and the levels returned to normal within 
4–8 weeks after treatment was stopped. No patient in the fumarate group had to stop 
treatment because of abnormal laboratory values. Transient elevation of liver enzymes 
of 100–200% of the value at screening visit were seen in eight (30%) of the 27 patients in 
the methotrexate group and three (11%) of the 27 patients in the fumarate group with 
the highest measured values being AST 71 U L-1, ALT 82 U L-1, GGT 80 U L-1. Moreover, 
five (19%) of the 27 patients in the fumarate group showed a transient eosinophilia 
(maximum measured level 1·55 X 109 L-1), but this was not observed in any patient in 
the methotrexate group. One (4%) of the 27 patients in the fumarate group showed 
a transient leucocytopenia (2·1 X 109 L-1), but this was not observed in any patient in 
the methotrexate group. One (4%) of the 27 patients in the methotrexate group had a 
transient thrombocytosis (with a maximum level of 422 X 109 L-1) that was not observed 
in any patient in the fumarate group. Transient lymphocytopenia (8% with a minimum 
level of 15%) was encountered in one (4%) of the 27 patients in the fumarate group, 
but was not observed in any patient in the methotrexate group. Eight (30%) of the 27 
patients in the fumarate group and eight (30%) of the 27 patients in the methotrexate 
group showed a transient proteinuria.
DISCUSSION
In this study in patients with moderate to severe psoriasis vulgaris, we noted that 
methotrexate and fumarates were equally effective at week 12 (Fig. 2). After 12 weeks 
of treatment, the mean adjusted absolute difference between the groups was only 1.4 
points. The PASI started to decrease in both the groups once treatment was started. 
Eleven (42%) of the 26 evaluated patients in the fumarate group and 15 (60%) of the 25 
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evaluated patients in the methotrexate group had a ‡ 50% reduction in PASI (P = 0.325). 
There were no significant differences in the efficacy except in week 4 (P = 0.001) when 
the PASI in the methotrexate group had decreased more rap- idly than in the fumarate 
group, which was already expected because of the known long induction time of fu-
marates. The recruitment phase was slow (October 2006 until February 2009). Most of 
the patients preferred to be treated with fumarates and did not want to take the risk of 
being randomized into the methotrexate group because they were afraid of the adverse 
events, mainly hepatotoxicity.
In our study we used a starting dose of 5 mg followed by 15 mg of methotrexate per 
week and tapered it off in the last 4 weeks (from week 12). We chose this dose follow-
ing the reported randomized study by Heydendael et al.9 who compared the efficacy 
of methotrexate and ciclosporin in the absence of evidence from dose-finding and 
treatment-duration studies.
Biological agents have recently attracted much attention. To date, three biologicals 
(adalimumab, etanercept, infliximab) have been approved by the U.S. Food and Drug 
Administration for the treatment of psoriasis. However, a main concern with biologi-
cals is their higher costs as compared with those of the traditional systemic therapies. 
The estimated annual cost of treatment with biologicals may range from €9200 to €21 
200 per patient. Sizto et al.10 reported in their meta-analy- sis that methotrexate and 
ciclosporin were the most cost-effective treatments for moderate to severe psoriasis. 
However, while most cost-effective, neither methotrexate nor ciclosporin is recom-
mended for prolonged use in the majority of patients, because of their high potentials 
for long-term toxicity. Therefore, we believe that treatment with fumarates should be 
considered as a first-choice treatment for moderate to severe psoriasis because of its low 
costs as compared with those of biologicals, and proven long-term efficacy and safety.
The clinical efficacy and safety of fumarates was reported in two double-blind, 
placebo-controlled, randomized trials.5,11 In the European S3 guidelines, systemic 
therapy with fumaric acid esters is recommended especially for the long-term therapy 
of patients with moderate to severe psoriasis on the basis of the favourable benefit-risk 
profile.6 The product is highly practical.12
A major strength of this study is that it is the first prospective randomized multicentre 
clinical trial in an outpatient setting on the effectiveness and the adverse events profile 
of fumarates in moderate to severe psoriasis as compared with those of methotrexate. 
Moreover, costs play an important role in the decision making with regard to therapy 
in psoriasis. At present, methotrexate and fumarates are by far the cheapest systemic 
therapies in moderate to severe psoriasis: methotrexate costs €44.80 for 22.5 mg tablets 
once weekly for 1 month compared with fumarates which cost €98 for six tablets of 120 
mg daily for 1 month.
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A limitation of this study is that we did not measure the quality of life of the patients 
because it was designed primarily to compare the clinical effectiveness and the safety of 
both drugs. Future study designs should include the quality of life score as an additional 
assessment tool.
It is well known that UV radiation therapy followed by treatment with immunosup-
pressive drugs, especially ciclosporin, increases the risk of skin malignancies by 6.9 
fold.13 Therefore, there is a great need to offer an effective, patient- friendly and safe 
alternative to patients with moderate to severe psoriasis, especially young patients, who 
do not respond well to topical treatments. Fumarates are particularly suited as a first-line 
systemic therapy in such patients.
This randomized controlled trial adheres well to the requirements outlined in pub-
lished guidelines.
In conclusion, the results of this study showed that the effectiveness and the toler-
ability of fumarates were similar to those of methotrexate. Methotrexate is not recom-
mended for prolonged use because of its high potential for long-term toxicity, especially 
hepatotoxity and fatal adverse events. Fumarates have a good and sustained clinical 
efficacy that is statistically similar to that of methotrexate, combined with a favourable 
safety profile with no serious adverse events in long-term therapy. Further comparative 
studies are warranted to confirm the results of this study.14
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ABSTRACT
Background: Fumaric acid esters (FAEs) are considered an effective and safe long- term 
treatment for psoriasis. However, 30–40% of patients need to discontinue FAE treatment 
due to intolerable adverse events. 
Objectives: To assess whether the addition of cetirizine, an oral histamine-1 receptor 
antagonist, to FAEs would reduce the incidence of adverse events. 
Methods: In a randomized, double-blind, placebo-controlled trial, patients with 
psoriasis with a Psoriasis Area and Severity Index ≥ 10 starting an FAE up to a dose of 
dimethylfumarate 720 mg per day were randomized 1 : 1 to receive either additional 
cetirizine 10 mg once daily (n = 25) or placebo (n = 25) for 12 weeks. Randomization and 
treatment allocation were done at our hospital trial pharmacy. Primary outcomes were 
the incidence of adverse events and the proportion of patients discontinuing treatment. 
Results: Fifty patients (33 male, 17 female; median age 44 years) were enrolled. Addition 
of cetirizine did not reduce the incidence of adverse events compared with placebo (84% 
vs. 84%, P = 1.00). The types of adverse events were not different between the cetirizine 
and placebo groups, the most common being gastrointestinal complaints (68% vs. 64%) 
and flushes (60% vs. 48%). The proportion of patients discontinuing treatment was not 
statistically different between the cetirizine and placebo groups (24% vs. 32%, P = 0.53). 
Conclusions Addition of oral cetirizine 10 mg once daily to FAE treatment did not reduce 
adverse events in patients with psoriasis during the first 12 weeks of treatment. The 
mechanisms underlying FAE-induced gastrointestinal and flushing symptoms likely 
involve mediators other than histamine. 
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INTRODUCTION
Fumaric acid esters (FAEs), or fumarates, are small molecules with immunomodula-
tory properties.1 For over three decades, FAEs have been used as an oral treatment in 
patients with chronic plaque psoriasis, with a favourable long-term efficacy and safety 
profile.2,3 The efficacy of FAEs is comparable with that of methotrexate.4,5 To date, there 
are no indications that long-term FAE treatment is associated with an increased risk of 
malignancies or infections, making FAEs particularly suit- able for maintenance therapy 
of psoriasis.3,6 
An important limitation of FAE treatment is intolerable adverse events, which result 
in treatment discontinuation in 30–40% of patients.7,8 The most commonly occurring 
adverse events of FAEs are gastrointestinal complaints and flushing. These relatively 
mild but inconvenient side-effects occur pre- dominantly during the first 3 months 
of FAE treatment. In order to improve the tolerability of FAEs, the current guide- lines 
recommend slowly increasing the dosage of the FAE using a standardized progressive 
dosing regimen.2 In this dosing regimen, the maximum daily dosage of 720 mg dimeth-
ylfumarate is reached within 9 weeks. If patients have adverse events, it is advised that 
they increase the dosage more slowly, decrease the dosage, or temporarily stop the FAE. 
Another strategy pursued in daily clinical practice when patients on FAEs experience 
adverse events is to prescribe an oral histamine antagonist in order to decrease these 
symptoms.9,10 The adverse events frequently reported during FAE treatment are similar 
to several histamine-mediated symptoms, such as diarrhoea, abdominal complaints and 
flushing.11 Blocking histamine might therefore be helpful in decreasing these adverse 
events during FAE treatment. Furthermore, treatment with a histamine antagonist could 
have an additional clinical benefit in patients with psoriasis, as histamine antagonists 
may have antipsoriatic effects.12,13 However, to date there is no clear evidence that the 
addition of a histamine antagonist to FAE treatment improves the tolerability or the ef-
ficacy of FAE in the treatment of psoriasis. 
In this randomized placebo-controlled trial, we aimed to determine whether the 
addition of cetirizine, an oral histamine-1 receptor antagonist, to FAE treatment would 
reduce the incidence of adverse events in patients with moderate-to- severe plaque 
psoriasis. In addition, we aimed to assess whether the addition of cetirizine to FAE treat-
ment would increase the efficacy of the FAE. 
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PATIENTS AND METHODS 
Study design 
This was an investigator-initiated, single-centre, randomized, double-blind, placebo-
controlled trial conducted at the derma- tology outpatient clinic of Erasmus Medical 
Center, Rotterdam, The Netherlands in the period 2009–2012. This study was approved 
by the medical ethics committee of the Erasmus Medical Center (MEC 2005-500). The 
study was conducted according to the principles of the Declaration of Helsinki. All 
patients gave written informed consent. The trial protocol was 
registered at the Dutch Trial Registry (http://www.trialregis- ter.nl/) under registration 
number NTR744. There were no funding sources. 
Study population 
Eligible for inclusion were patients aged 18 years or older with moderate-to-severe 
chronic plaque psoriasis, who had a Psoriasis Area and Severity Index (PASI) ≥ 10 and 
who were candidates to start FAE treatment. The exclusion criteria were renal disease, 
liver disease, a medical history of malignancies, pregnancy and lactation. Patients had to 
discontinue all psoriasis treatments before enrolment, with a washout period of 4 weeks 
for systemic treatment and phototherapy, or 2 weeks for topical psoriasis treatment. 
During the study psoriasis treatments were not allowed expect for bland emollients. 
STUDY PROCEDURES 
Enrolled subjects were randomized at baseline in a 1:1 ratio to receive either FAE plus 
cetirizine 10 mg once daily or FAE plus a matching placebo for 12 weeks, followed by 
a follow- up period of 8 weeks. Randomization and treatment allocation were done at 
the hospital trial pharmacy. Patients and physician assessors were both blinded for the 
allocated treatment group. 
All patients were treated with a Dutch FAE formulation with enteric-coated tablets 
containing 105 mg FAE (30 mg dimethylfumarate and 75 mg calcium monoethylfu-
marate) for the first 3 weeks, followed by tablets of 215 mg FAE (120 mg dimethylfu-
marate and 95 mg calcium monoethylfumarate) (Pharmacy ‘De Magistrale Bereider’, 
Oud-Beijerland, The Netherlands). In previous studies we analysed this FAE formulation 
for pharmacokinetic properties and for efficacy compared with methotrexate.4,14 FAEs 
were given according to a standardized progressive dosing regimen, starting at 30 mg 
dimethylfumarate per day with an incremental increase up to a maximum daily dosage 
of 720 mg dimethylfumarate within 9 weeks.2 
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Patients were seen at weeks 0, 4, 8, 12 and 20. At each study visit adverse events were 
reviewed and routine laboratory testing was performed: full blood count with differ-
ential, liver function tests, serum creatinine levels, cholesterol levels and urine analysis. 
Furthermore, PASI was recorded at each study visit, and health-related quality of life 
was measured using the Skindex-29 questionnaire at week 0 and week 12. Skindex-29 is 
a validated questionnaire that measures dermatology-specific health-related quality of 
life on a scale ranging from 0 to 100, with higher scores indicating lower quality of life.15 
There are currently several instruments available to measure dermatology-specific 
health-related quality of life, but there is no clear consensus on which instrument to 
use.16 The Dermatology Life Quality Index is a widely used instrument, but there are 
some limitations to its use.17 At our department the Skindex-29 questionnaire is routinely 
used in daily clinical practice to measure dermatology-specific health-related quality of 
life. Therefore, we chose to use Skindex-29 in this study. 
Outcomes
The primary outcomes were the incidence of adverse events and the proportion of 
patients discontinuing FAE treatment. Secondary outcomes were changes in PASI and 
changes in health-related quality of life. 
Statistical analysis
Data are presented as mean ±SD, or as median with inter- quartile range (IQR) when not 
normally distributed. Analysis was by intention to treat. Differences in categorical vari-
ables and continuous variables between the two groups were tested with the Kruskal–
Wallis or v2-test, respectively. A P-value ≤ 0.05 was considered statistically significant. 
We calculated a sample size of 50 patients to give 90% power with a two-sided 5% 
significance level to detect a reduction of 55% in the incidence of adverse events. 
RESULTS
Patient characteristics
In total, 50 patients were enrolled and included in the trial (Fig. 1). The demographic 
and clinical characteristics of the study population are summarized in Table 1. The me-
dian age was 44 years (IQR 30–56) and the median duration of psoriasis was 11 years 
(IQR 5–21). Most patients had been treated previously with phototherapy (36%). Few 
patients had been previously treated with a classical systemic psoriasis treatment (28%) 
or with a biological (4%). 
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Incidences of adverse events during FAE treatment 
Overall, 21 (84%) of 25 patients in the cetirizine group and 21 (84%) of 25 patients in 
the placebo group experienced an adverse event during the first 12weeks of treatment 
(Table 2). The addition of cetirizine to the FAE did not reduce the incidence of adverse 
events in the cetirizine group com- pared with the placebo group (84% vs. 84%, P = 
1.00). 
The most common adverse events in the cetirizine group were gastrointestinal 
complaints (68%), flushes (60%) and pruritus (28%). Similar frequencies were observed 
in the placebo group, with the most commonly reported adverse events being gastro-
intestinal complaints (64%), flushes (48%) and headache (28%). The incidences of the 
different types of adverse events were not significantly different between the cetirizine 
and placebo groups. There were no differences between the two groups in the 8-week 
follow-up period following week 12. 
 
Assessed for eligibility (n=61) 
Excluded  (n=11) 
i   Not meeting inclusion criteria (n=8) 
i   Declined to participate (n=3) 
 
Analysed  (n=25) 
Discontinued treatment (n=6): 
i Gastrointestinal complaints (n=3) 
i Increase of psoriasis (n=1) 
i Arrhythmia (n=1) 
i Myocardial infarction (n=1) 
Lost to follow up (n=2) 
 
Allocated to FAE plus cetirizine (n=25) 
i Received allocated intervention (n=25) 
Discontinued treatment (n=8): 
i Gastrointestinal complaints (n=3) 
i Increase in liver enzymes (n=1) 
i Arrhythmia (n=1) 
i Pregnancy (n=1) 
i Tinnitus (n=1) 
i Chest pain (n=1) 
Lost to follow up (n=2) 
Allocated to FAE plus placebo (n=25) 
i Received allocated intervention (n=25) 
Analysed  (n=25) 
Allocation 
Analysis 
Follow-Up 
Randomized (n=50) 
Enrollment 
Figure 1: Flow diagram
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Tolerability
Six (24%) of 25 patients in the cetirizine group had discontinued FAE treatment. The 
reasons for discontinuing treatment were intolerable gastrointestinal complaints (n=3), 
an increase of psoriasis (n=1), arrhythmia (n=1), and myocardial infarction (n=1). In the 
placebo group the number of patients discontinuing FAE treatment was slightly higher, 
with 8 (32%) of 25 patients who discontinued treatment. The reasons for discontinuing 
treatment were gastrointestinal complaints (n=3), an increase in liver enzymes (n=1), 
arrhythmia (n=1), pregnancy (n=1), tinnitus (n=1), and chest pain (n=1). The proportion 
Table 1: Baseline demographic and clinical characteristics of the study population
Characteristic FAE with 
cetirizine
(n=25)
FAE with placebo 
(n=25)
Age 46 (31-62) 38 (30-54)
Sex 
Male 15 (60%) 18 (72%) 
Female 10 (40%) 7 (28%) 
Duration of psoriasis in years 11 (5-19) 12 (5-24)
History of psoriatic arthritis 8 (32%) 5 (20%)
Previous psoriasis treatments
Phototherapy 10 (40%) 8 (32%)
Classical treatment (methotrexate, ciclosporin) 8 (32%) 6 (24%)
Biologic treatment 2 (8%) 0 (0%)
PASI at baseline 12.7 (10.8-16.0) 14.5 (12.0-16.7)
Data are numbers (percentages) or medians (interquartile ranges)
Table 2: Subjective adverse events 
Characteristic FAE with cetirizine
(N = 25)
FAE with placebo 
(N = 25)
Gastrointestinal complaints 17 (68%) 16 (64%)
Flushing 15 (60%) 12 (48%)
Pruritus 7 (28%) 6 (24%)
Headache 2 (8%) 7 (28%)
Fatigue 5 (20%) 4 (16%)
Lower extremity edema 2 (8%) 2 (8%)
Dermatitis 0 (0%) 1 (4%)
Chest pain 0 (0%) 1 (4%)
Tinnitus 0 (0%) 1 (4%)
Flu-like symptoms 1 (4%) 0 (0%)
Dizziness 1 (4%) 0 (0%)
Data are numbers (percentages) 
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of patients discontinuing FAE treatment was not statistically different between the 
cetirizine and the placebo group (P=0.53).  There were two (8%) patients in the placebo-
group and two (8%) patients in the cetirizine-group who were lost to follow up. 
Safety
Abnormal laboratory tests were observed in 24 (96%) patients of the cetirizine group 
versus 21 (84%) patients in the placebo group (Table 3). The most common abnormal 
laboratory tests seen in both groups were an increase in liver enzymes, an eosinophilia, 
and a proteinuria. A decrease in lymphocyte counts was seen in 5 (20%) patients treated 
with additional cetirizine versus 4 (16%) patients in the group who received placebo. In 
all cases the laboratory abnormalities were mild with changes of less than twofold the 
limits of normal value, and all laboratory abnormalities normalized without any inter-
vention and while continuing FAE treatment. There was only 1 (4%) patient in the FAE 
plus cetirizine group who had a more than twofold increase in alanine transaminase and 
in aspartate transaminase following 4 weeks of treatment with FAE and who therefore 
had to discontinue FAE treatment. The increase in transaminases normalised within 2 
weeks.      
Efficacy
The median improvement in PASI at week 12 compared to baseline was 65% (IQR 52-79) 
among patients treated with FAE plus cetirizine (Fig. 2). In the group of patients receiv-
ing FAE plus placebo a similar improvement in PASI at week 12 was seen, with a median 
improvement of 66% (IQR 49-78). The proportion of patients achieving at least 75% 
improvement in PASI at week 12 was 20% in both the cetirizine group and the placebo 
group. 
Table 3: Laboratory adverse events 
Characteristic FAE with cetirizine
(N = 25)
FAE with placebo 
(N = 25)
Increase in liver enzymes 13 (52%) 15 (60%)
Eosinophilia 10 (40%) 8 (32%)
Proteinuria 8 (32%) 5 (20%)
Lymphocytopenia 5 (20%) 4 (16%)
Decrease in creatinine 4 (16%) 0 (0%)
Increase in urea 2 (8%) 1 (4%)
Increase in cholesterol 2 (8%) 1 (4%)
Decrease in thrombocytes 0 (0%) 1 (4%)
Increase in haemoglobin 1 (4%) 0 (0%
Data are numbers (percentages) 
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Health-related quality of life
The health-related quality of life as measured by the Skindex-29 improved during the 
12-week FAE treatment (Fig. 3). In the group of patients treated with FAE plus cetiri-
zine the median improvement at week 12 was 39% (IQR 20-62). Among patients who 
received FAE plus placebo the median improvement at week 12 was 55% (IQR 21-77). 
The improvements in Skindex-29 scores were not statistically different between the 
cetirizine and the placebo group (P=0.87).
Figure 2: changes in PASI during 12 weeks of FAE treatment in patients treated with FAE plus cetirizine 
(n=25) and in patients treated with FAE plus placebo (n=25). Error bars show median and interquartile 
range. 
Figure 3: changes in Skindex-29 scores during 12 weeks of FAE treatment in patients treated with FAE 
plus cetirizine (n=25) and in patients treated with FAE plus placebo (n=25). Error bars show median and 
interquartile range.
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DISCUSSION
In this randomized double-blind placebo-controlled trial among 50 patients with 
moderate-to- severe psoriasis treated with FAE for 12 weeks, the addition of the oral 
histamine-1 receptor antagonist cetirizine 10 mg once daily to FAE did not reduce or 
improve the tolerability of FAE treatment. Furthermore, the addition of cetirizine did not 
increase the efficacy of FAE compared to treatment with FAE alone.
To translate these findings into implications for clinical practice, several aspects of 
our study need to be considered. Firstly, we used a randomized, double-blind study 
design and a matching placebo for cetirizine so that both the patients and the physician 
assessors were blinded for the allocated treatment group. Secondly, we used a suitable 
histamine-1 receptor antagonist that has shown to be well-tolerated with favourable 
pharmacological properties in other patient populations.18 In addition, the effects of 
cetirizine were studied previously in patients with psoriasis.12,19 A limitation of our study 
is the relatively small sample size, owing to our pre-study power calculation. However, 
if a greater sample size were required to detect a statistically significant difference, the 
clinical value of adding a histamine antagonist to FAE would likely be small. Furthermore, 
we did not quantify the severity of flushing and gastrointestinal symptoms. However, 
we did look specifically for the incidence of adverse events requiring FAE treatment 
discontinuation, for which we found no statistically significant differences between the 
cetirizine and placebo groups. Lastly, we chose a Short-term study duration of 12 weeks, 
considering that adverse events occur predominantly at the beginning of FAE treatment. 
In this study, treatment with an oral histamine-antagonist had no effect on the occurrence 
of the adverse events during FAE treatment. Therefore, the mechanisms underlying FAE-
induced gastrointestinal and flushing symptoms likely involve mediators other than hista-
mine. Alternatively, histamine may play only a minor role in the generation of adverse events 
associated with FAE. In recent experimental studies it has been shown that FAE-induced 
flushing is mediated through activation of the G-protein-coupled receptor GPR109A located 
on Langerhans cells and on keratinocytes, which via cyclooxygenase-1 and -2 enzymes leads 
to prostaglandin release.20 Further evidence for this mechanism comes from a clinical trial 
involving 56 healthy volunteers, in which aspirin, a cyclooxygenase inhibitor, decreased the 
incidence and severity of flushing symptoms of dimethylfumarate.21  
The mechanisms leading to gastrointestinal complaints in FAE treatment are not yet 
understood. One hypothesis involves the FAE-triggered release of tumour necrosis fac-
tor alpha (TNF-α) as a mechanism leading to gastrointestinal complaints.22 In a previous 
clinical study, co-treatment of FAE with pentoxifylline, a methylxanthine derivative with 
some anti-TNF-α properties, reduced the frequency of gastrointestinal complaints.23 This 
study, however, was open-label and uncontrolled so that bias of these results cannot be 
excluded. Another potential mechanism may involve dimethylfumarate-induced allergic 
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contact mucositis of the gastrointestinal tract.24 Hessam et al.24 described three patients 
who had to discontinue FAE due to gastrointestinal complaints and who had a positive 
patch test reaction to dimethylfumarate. Considering that dimethylfumarate is a potent 
contact sensitizer, systemic treatment with dimethylfumarate could induce an allergic 
contact mucositis, and thus causing gastrointestinal symptoms. Future studies could 
focus on these mechanisms to find new strategies to improve the tolerability of FAEs.
In this study, cetirizine at a daily dosage of 10 mg did not reduce FAE-induced adverse 
events. One can speculate whether higher dosages of cetirizine may be more effec-
tive. In the cur- rent guidelines on the treatment of chronic urticaria, the daily dose of 
cetirizine may be increased up to fourfold when a single dose of cetirizine 10 mg is inef-
fective.25 Similarly, cetirizine in higher doses might be effective to decrease FAE-induced 
adverse events. We did not test this hypothesis in this current study. 
 It has been suggested that the histamine-antagonist cetirizine may be beneficial in 
psoriasis treatment.12,26 In this study, we could not detect an additional improvement by 
cetirizine. The improvement in PASI in the FAE plus cetirizine group was equal compared 
to treatment with FAE alone. Other histamine antagonists like ranitidine, a histamine-2 
receptor antagonist, did show improvements of psoriasis in several observational stud-
ies but failed to demonstrate efficacy in randomized controlled trials.27,28 
FAE have a favourable long-term efficacy and safety profile, but the induction phase 
of FAE treatment can be challenging for patients because of problems with tolerability. 
Therefore, a gradual increase in dose of FAE is considered standard. A large disadvantage 
of this approach is that it takes longer to reach the dosage with a satisfactory clinical 
response. In daily clinical practice, the first clinical response is usually observed fol-
lowing 6 to 8 weeks of treatment.2 If FAE-induced adverse events can be decreased or 
even prevented, the optimal dosage of FAE could be reached faster and would thereby 
increase patient treatment satisfaction. There is evidence that aspirin and non-steroidal 
anti-inflammatory drugs decrease flushing symptoms, but these drugs to do not affect 
gastrointestinal complaint. It is our experience that patients on FAE find the gastroin-
testinal symptoms to be more bothersome that the flushing symptoms. In this study, 
there were 6 of 50 patients who discontinued FAE due to gastrointestinal complaints 
and none who had to discontinue FAE due to flushing. In daily clinical practice, gastro-
intestinal complaints can be managed by symptomatic treatment with proton pump 
inhibitors, anti-emetics, or anti-diarrhoeal drugs.10 Given the results of this study, adding 
a histamine antagonist to FAE is not helpful in reducing the adverse events.       
In conclusion, the addition of the histamine antagonist cetirizine 10 mg once daily to 
FAE treatment did not reduce adverse events nor improved tolerability of FAE in psoria-
sis patients. Our results do not support a beneficial effect of adding a systemic histamine 
antagonist to FAE treatment in patients with psoriasis. 
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ABSTRACT
Background: Psoriasis vulgaris is a T cell-mediated disease that affects 2-3% of the 
worldwide white-skinned population. Fumaric acid esters are mentioned as an effective 
therapy for moderate to severe psoriasis vulgaris in adult patients in the new guidelines 
for psoriasis treatment.
Objectives: To obtain an insight into the use of fumaric acid esters by Dutch dermatolo-
gists in the Netherlands.
Methods: This was a cross-sectional postal survey. An anonymous survey was posted to 
all Dutch dermatologists. In this survey, data was collected on the extent of fumaric acid 
esters use, the reasons for use, the reasons for non- or limited use of fumaric acid esters, 
the perception of fumaric acid esters as a mono-therapy with regards to the effective-
ness, the safety, the adverse events and the overall satisfaction of fumaric acid esters as 
a mono-therapy.
Results: Sixty-three per cent of the 300 responders indicated to prescribe fumaric acid 
esters for the treatment of psoriasis. About 37% of the dermatologists indicated (almost) 
never to prescribe it. Biologicals were considered as the most effective therapy. Fumaric 
acid esters were regarded as the safest therapy. They were generally well tolerated by 
the patients similar to that for methotrexate according to the respondents.
Conclusion: A large proportion of the dermatologists in our survey indicated to pre-
scribe fumaric acid esters. It is considered to be effective, safe and without adverse 
events profile that is favourable in the practice, also as compared with other systemic 
therapies such as methotrexate and biologicals.
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INTRODUCTION
Psoriasis vulgaris is a T cell-mediated disease that affects 2-3% of the worldwide white-
skinned population.1,2,3 Systemic therapy is often limited because prolonged use of 
effective doses may lead to severe adverse events.4
Fumaric acid esters (FAE) were specifically developed to treat psoriasis vulgaris and 
were first used in Germany in 1959, where they have been registered for the treatment 
of psoriasis since 1995.5,6 However in many other countries this is not the case.
Dimethylfumarate and monoethylfumarate are the used esthers.7The most active 
metabolite is monomethylfumarate that is formed after absorption and hydrolysis of 
dimethylfumarate. The mode of action of FAE consists of inhibition of both the T cell 
activity and the keratinocyte proliferation.
Recently, Fallah Arani et al. published in the only prospective randomized study that 
FAE were as effective as methotrexate in the treatment of psoriasis.8
Treatment with FAE is mentioned in several guidelines as an effective induction 
therapy for moderate to severe psoriasis vulgaris in adult patients.9, 10
The aim of this nationwide survey was to obtain an insight into the use of FAE by Dutch 
dermatologists in the Netherlands, although FAE are not registered in the Netherlands. 
For this purpose, it was assumed that FAE were mainly prescribed by dermatologists in 
the Netherlands.
METHODS
Study design
This is a cross-sectional postal survey. An anonymous survey was posted to all mem-
bers of the Dutch Society of Dermatology and Venereology (NVDV), which includes all 
practising dutch dermatologists and residents in the Netherlands. All the members of 
the NVDV received a letter announcing our survey and two full questionnaires between 
April and August 2010. Non-responders were sent a reminder letter and the question-
naire once more. The completed questionnaires were processed anonymously (only on 
the basis of zipcode). Subsequently, postcodes with non-responders were mailed the 
questionnaire again.
The total response after the first round was 33%, which increased to 50% after the 
second round.
Data collection
Data on the extent of FAE use, the reasons for use, the reasons for non- or limited use 
of FAE; the perception of FAE as a mono-therapy with regards to the effectiveness, the 
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safety, the adverse events and the overall satisfaction of FAE as a mono-therapy was 
collected in this survey. In addition, we also included questions involving other systemic 
treatments for psoriasis vulgaris so as to enable an indirect comparison between FAE 
and various other systemic treatments.
The group of patients with mild disease who did not require systemic treatment was 
excluded.
RESULTS
General information on respondents
More than 75% of the respondents were dermatologists, the remaining were residents 
in dermatology. From here onwards residents in dermatology are included when “der-
matologists” are mentioned.
A total of 300 dermatologists responded. The largest proportion of the respondents 
(66%) had a peripheral hospital as their primary work address, that is to say the work ad-
dress at which most of the patients were treated. About 24% of the respondents worked 
at a teaching hospital, and the remaining 10% at a Healthcare centre or at another type 
of location. More than 61% were practicing dermatologists for 10 years or longer. A 
considerably smaller proportion of the responders were practicing dermatologists for 
either 5 to 10 years (18%), or 2 to 5 years (13%), or less than 2 years (8%).
About 11% of the respondents indicated to treat 20 to 50 patients with moderate to 
severe psoriasis per week. A larger proportion (37%) treated 10 to 20 patients per week. 
More than half of the dermatologists treated 10 patients or less per week.
More than half of the respondents reported that up to 30% of their patients with 
moderate to severe psoriasis would qualify for a systemic treatment or for phototherapy. 
Only a small proportion of the respondents indicated that 50% or more of their patients 
had moderate to severe psoriasis.
Use of fumaric acid esters in psoriasis vulgaris
189 (63%) of the responders indicated to prescribe FAE for the treatment of psoriasis. 
About 103 (35%) of the dermatologists indicated (almost) never to prescribe FAE. The 
most important reasons for not prescribing FAE were lack of experience during resi-
dency, no experience, and that FAE were not registered in the Netherlands.
From these about 20(19.4%) from the 103 respondents indicated that there were 
no thinkable circumstances under which they would be willing to prescribe FAE. The 
remaining 83 (81%) respondents were willing to prescribe FAE for patients who did not 
respond to other systemic therapies or when more clinical studies were under taken.
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The 189 (63%) dermatologists who did prescribe FAE did so mainly because of good 
experiences with the therapy and because of few serious adverse events due to its long-
term effectiveness and safety.
In the daily practice, FAE were generally prescribed as a mono-therapy or started as a 
mono-therapy and then combined. More than 120 (40%) of the respondents indicated 
to directly combine it mainly with topical vitamin D3-preparations or topical corticoste-
roids.
Phototherapy
It appeared from the various types of phototherapy that were used at the dermatologi-
cal out-patient department that UV-B therapy was the most popular followed by UV-B 
home therapy. PUVA, used either as bath or non-bath PUVA was almost never used by 
most of the dermatologists.
Systemic therapies
It appeared that oral methotrexate was used the most followed by cyclosporine and 
acitretin.
Etanercept (Enbrel®) was prescribed the most from the biologicals, followed by adali-
mumab (Humira®), infliximab (Remicade®) and the more recently available ustekinumab 
(Stelara®) to treat psoriasis.
Perception of systemic therapies
Finally, the picture of various systemic therapies with respect to their effectiveness, 
their safety, (not serious) adverse events and the general satisfaction was requested. It 
was mentioned for all criteria that it concerned the picture as a mono-therapy and that 
it involved “own experience” and did not involve the results of clinical investigations 
known to the respondents. On each of the 4 criteria, a report figure of 1 (“very poor”) 
to and including 10 (“very good”), or that one had no experience with a certain therapy 
could be given per systemic therapy. The latter was not included in de next evaluation.
Effectiveness as mono-therapy
Biologicals are considered as the most effective therapy, whereby etanercept (Enbrel®) 
is considered to be slightly less effective than the other three Methotrexate (oral or via 
injection) is considered to be almost as effective as etanercept (Enbrel®). Cyclosporine in 
turn is considered to be somewhat less effective than methotrexate, but as somewhat 
more effective than FAE (Figure 1).
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Safety as mono-therapy
Safety is defined here as “the absence of serious adverse events”. FAE are regarded as the 
safest therapy for psoriasis vulgaris followed by the rest at some distance. The biologi-
cals also lie close together in this respect, whereby infliximab (Remicade®) also scores 
somewhat lower than the rest of the biologicals in this respect. Cyclosporine has the 
worst score in the safety criterion (Figure 2).
Adverse events as mono-therapy
The criterion “adverse events” was defined in the questionnaire as “the occurrence of 
non-serious adverse events”. Respondents generally consider the biologicals to be 
slightly better than the other therapies. Similar to methotrexate, FAE are generally well-
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Figure 1. Perception of efficacy per treatment (as mono-therapy).
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Figure 2. Perception of safety per treatment (as mono-therapy).
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tolerated by the patients according to the respondents. This is less valid for cyclosporine 
and acitretin (Figure 3).
Satisfaction as mono-therapy
The complete picture of the effectiveness, the safety and the adverse events is under-
stood under “Satisfaction”. It appears from Figure 4 that the various drugs differed very 
little form each other as far as the dermatologists were concerned. Only cyclosporine 
and acitretin scored lower than the rest, but still narrowly achieved an adequate.
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Figure 3. Perception of the adverse events per treatment (as mono-therapy).
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Figure 4. Overall satisfaction per treatment (as mono-therapy).
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DISCUSSION
This survey was set-up to obtain an insight on the use of FAE in the Netherlands and 
to assess the attitudes of Dutch dermatologists towards the use of FAE. The position of 
FAE appeared to be more favourable than would be expected. A large proportion of the 
dermatologists in our survey indicated to prescribe FAE although they are not registered 
yet in the Netherlands and are magisterially prepared in the absence of industrial pro-
duction according to good manufacturing practice (GMP) standards. The dermatologists 
who did prescribe FAE were generally satisfied to very satisfied.
This survey provides a clearer picture on the systemic therapies for psoriasis vulgaris 
on the basis of the high response rate. To our knowledge, a similar survey as that re-
ported here has not been undertaken previously in the Netherlands. Nonetheless, this 
survey may have certain limitations. Our results may be biased because dermatologists 
who are in favour of using FAE were probably more inclined to participate in this survey 
than those who did not use FAE or reverse. We do not have data on non-responders. 
Therefore, we cannot fully exclude response bias.
FAE-therapy is considered to be effective, safe and without adverse events profile 
that is favourable in the daily practice also as compared with other systemic therapies 
such as methotrexate and biologicals. They are a relatively inexpensive, certainly as 
compared with biologicals. Based on this one can recommend registration of FAE and 
for its industrial production according to the GMP standards.
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ABSTRACT
Fumarates or fumaric acid esters derivates (FAED) have appeared to be as effective and 
less toxic than other systemic treatments for psoriasis. Due to it’s safe adverse event 
profile FAED can be used as a long-term maintenance therapy. One of the greatest 
reasons why FAED are not preferred as a first line treatment is that according to the 
recommended dosing schedule, clinically meaningful improvement is seen just after 6 
to 8 weeks of therapy. In this manuscript we suppose an alternative induction scheme 
with a combination therapy of fumarates and cyclosporine for a more rapid improve-
ment and better compliance.
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Induction therapy with a combination of fumarates and cyclosporine
A broad spectrum of anti-psoriatic treatments such as fumarates are available in the 
management of psoriasis. Evidence-based guidelines can be used for this however 
mostly only a tailor made treatment will fulfill patient’s needs.1 One of these needs is to 
achieve a more rapid reduction in the treatment with fumarates in moderate-to-severe 
psoriasis patients with a minimum of adverse events?
Fumarates or fumaric acid esters derivates (FAED) have appeared to be as effective 
and less toxic than other systemic treatments for psoriasis.2,3 Due to it’s safe adverse 
event profile FAED can be used as a long-term maintenance therapy.4 One of the great-
est reasons why FAED are not preferred as a first line treatment for moderate-to-severe 
psoriasis is that according to the recommended dosing schedule, clinically meaningful 
improvement is seen just after 6 to 8 weeks of therapy. This has an impact on the compli-
ance, which already is affected by several adverse events such as flushing and nausea 
occurring in the induction phase of the FAED therapy. A quick induction of the clinical 
efficacy will increase the compliance and patients will be more willing to continue FAED 
therapy. Therefore we would like to propose an alternative induction dosage regimen, 
which includes a combination between FAED with another anti-psoriatic drug. Little is 
known about combinations of FAED with other systemic drugs. In some case reports 
successful combination with other systemic agents such as methotrexate and cyclospo-
rine are reported, where FAED generally enabled the doses of the more hazardous drugs 
to be reduced.3
The European S3-guidelines on the systemic treatment for psoriasis vulgaris recom-
mend cyclosporine primarily for induction therapy, because of its rapid efficacy.1 
Cyclosporine is a calcineurin inhibitor and immune modulator and inhibits the produc-
tion pro-inflammatory cytokines and activity of T lymphocytes. Clinical improvement 
of psoriasis occurs after approximately 4 weeks, and maximum response is seen after 
about 8 to 16 weeks. 1 Cyclosporine would be the best candidate to combine with FAED 
for a rapid induction.
Therefore we would like to introduce an alternative starting dosage scheme for 
therapy with FAED and cyclosporine, which will give a quick satisfactory improvement 
of psoriasis with a relatively low adverse event profile:
FAED can be given according to the established dosage scheme (fig. 1) starting of with 
FAED 120mg once daily Next to FAED cyclosporine can be started with 5 mg/kg daily.
Since Wilsmann-Theis et al. have recently described 2 patients with severe psoriasis 
vulgaris being treated with a combination of FAED and cyclosporine whereby therapy 
with cyclosporine was stopped in one patient already after 6 weeks after achieving a 
PASI reduction from 12.0 to 3.0,6 we expect a PASI 50% reduction after 2 weeks of treat-
ment. Cyclosporine can be stopped after reaching 80% from the maximum dosage of 
FAED depending on the PASI reduction or with a PASI reduction of 50% but not later 
than week 12. FAED can be continued according to the established dosage scheme to 
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a maximum dosage of 740mg per day as a single treatment. We expect improvement 
of the PASI score (PASI 50%) after 2 weeks with 120mg FAED in combination with cyclo-
sporine, which will enhance the overall adherence. The dosage of FAED is dependent on 
each individual patient and his/her response to therapy and can be managed during the 
long-term maintenance treatment by lowering or increasing de dosage with not more 
than 1 tablet of 120 mg daily per week.4
Laboratory, urine analyses, and blood pressure measurements are mandatory as 
usual.3 Since FAED and cyclosporine are immunosuppressive agents screening for 
hepatitis B, C, HIV and active infections including history of recurring or persistent infec-
tions or underlying conditions that may predispose to infections (e.g. chest infections 
or previous septic joint in situ) and tuberculosis (Mantoux-test) are necessary before 
starting the therapy.
Recently cases of progressive multifocal leukoencephalopathy (PML) caused by JC 
virus have been reported in patients treated with FAED, therefore monitoring of the 
blood count is important, since FAED are known to induce lymphocytopenia and leuco-
cytopenia.5 If leucocytes drop below 3000/μL and lymphocytes below 500/μL, the dose 
must be reduced or the treatment stopped.1
Figure 1. Dosage induction scheme for FAED and cyclosporine
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Although there is limited experience in combination therapy with FAED and cyclo-
sporine 3,6, we believe that this alternative treatment induction scheme can be ben-
eficial and a fast, cost-effective and safe alternative, especially compared to the more 
expensive biologic therapies. In the literature no evidence of any clinically significant 
drug interactions has emerged when FAED treatment was combined with cyclosporine, 
acitretin, hydroxyurea and methotrexate.3 Nevertheless frequent laboratory monitoring 
is mandatory. This combination therapy is more cost-effective comparing to the expen-
sive biologic therapies and can enhance efficacy and especially compliance, which often 
leads to discontinuation of therapy in patients with psoriasis.
Figure 2. Dosage/efficacy of FAED and cyclosporine till week 12 and after:
Cyclosporine can be stopped whether after reaching 80% from the maximum dosage of FAED depending 
on the PASI reduction at week 12.
FAED can be continued according to the established dosage scheme to a maximum of 6 tablets of 120mg 
(740mg) daily and continued as a single treatment. Depending on the individual PASI reduction FAED can 
be gradually decreased to 1 or 2 tablets of 120mg (120 – 240 mg) daily as a maintenance therapy.
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ABSTRACT
Background: Psoriasis is a chronic inflammatory T-cell mediated skin disease. Mycophe-
nolate mofetil is a well known immunosuppressive agent in transplantation medicine. 
The efficacy of enteric-coated mycophenolate sodium (EC-MPS) was confirmed in other 
inflammatory skin diseases, including atopic dermatitis and subacute cutaneous lupus 
erythematosus.
Objective: To investigate the efficacy and the tolerability / short term safety of enteric-
coated mycophenolate sodium (EC-MPS) in patients with moderate to severe chronic 
plaque psoriasis.
Patients and methods: An open label pilot study in which 20 patients with a Psoriasis 
Area and Severity Index (PASI) >10 received EC-MPS 720 mg twice daily for 6 weeks fol-
lowed by 360 mg twice daily for another 6 weeks. Patients who completed the 12-weeks 
of treatment were followed up for an additional 12 weeks. Treatment outcomes were 
assessed with PASI50% and PASI75%.
Results: 18 males and 2 females (mean age 46 years) entered the study. 65% (13/20) 
finished the treatment period. In week 6, no patient achieved PASI75% and 8/20 patients 
achieved a PASI50%. Compared to week 6, 4/13 showed a deterioration of their psoriasis 
at week 12. 25% (2/8), achieved a PASI 75% in week 24. The most reported adverse events 
were itching (30%), diarrhea (10%) and a reversible elevation of the triglycerides level.
Conclusion: EC-MPS does not seem effective as monotherapy for moderate to severe 
psoriasis, but might be used at a dosage of 1440mg daily in well-selected patients with 
treatment resistant psoriasis. The treatment was reasonably tolerated with no serious 
adverse events.
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INTRODUCTION
Psoriasis is a chronic inflammatory, T-cell mediated, skin disease that worldwide affects 
2% of the population (ref Stern et al, 2004). Currently there are several topical and sys-
temic treatment options for psoriasis. Whereas topical treatments are usually prescribed 
when skin lesions are confined to small areas, phototherapy and systemic treatments 
are used when extensive involvement of the skin is present. Potentially serious adverse 
effects often hamper the continuous use of some systemic antipsoriatic agents.
Mycophenolate mofetil (MMF) is an immunosuppressive drug containing mycophe-
nolic acid (MPA) as the active substance. It is widely used in the prevention of organ 
allograft rejection [1]. More recently its use has been expanded to successfully treat sev-
eral autoimmune and inflammatory skin disorders, including atopic dermatitis, subacute 
cutaneous lupus erythematosus (SCLE) and psoriasis [2, 3]. MPA is a potent and selective 
inhibitor of IMPDH (inosine monophosphate dehydrogenase), the control enzyme of the 
de novo synthesis of guanosine nucleotides in purine metabolism, and hence also a 
potent inhibitor of DNA and RNA synthesis in activated T cells [4]. Inhibition of lympho-
cyte proliferation reduces this predominant inflammatory cell type in psoriatic lesions 
and indirectly reduces the hyperproliferation of epidermal keratinocytes. A number of 
adverse effects are associated with the use of MMF such as hematological disorders, 
lymphoproliferative disease, increased risk of opportunistic infections (particularly cy-
tomegalovirus) and gastrointestinal (GI) disorders (e.g. nausea, vomiting, diarrhea and 
gastritis), which limits its widespread use in clinical settings. To reduce the GI adverse 
events of MMF, enteric-coated mycophenolate sodium (EC-MPS), a prodrug of MMF, was 
designed that delays the release of MPA until reaching the small intestine. At a dose of 
720 mg, EC-MPS exhibits equivalent MPA exposure and maximal MPA concentration to 
MMF 1000 mg [5]. Studies have confirmed that patients with a maintenance MMF dos-
age regimen can be safely converted from MMF to EC-MPS without change in efficacy 
or safety profile. Therefore, EC-MPS appears to be a valid alternative MPA therapy with 
a comparable efficacy and safety profile to MMF with improved GI tolerability [5]. If ef-
fective, EC-MPS may be useful for psoriasis patients contraindicated or resistant to other 
conventional and systemic drugs. The choice for the systemic treatment of psoriasis 
beside biologicals is mainly limited to Methotrexate (MTX) and cyclosporine. There is 
certainly a need for more drugs, especially those with a favorable risk/benefit ratio. For 
this reason we studied the possible role of MPA in psoriasis treatment.
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PATIENTS AND METHODS
Study population
Patients were eligible to enter this open label study if they were at least 18 years of age 
and had a clinical diagnosis of moderate to severe stable psoriasis vulgaris (PASI > 10) at 
baseline. Consecutive patients at the Department of Dermatology of Erasmus MC were 
screened and invited to participate. Subjects were excluded if they had any other chronic 
internal diseases, chronic co-medication, were female and pregnant or breastfeeding or 
considering becoming pregnant during the study, had a history of clinically significant 
drug or alcohol abuse in the last year, had a positive test result for hepatitis B, C or HIV, 
had a history of opportunistic infections and are known to have a hereditary deficiency 
of the hypoxanthineguanine-phosphoribosyl-transferase (HGPRT).
All subjects provided written informed consent before inclusion into the study. The 
medical ethical commission of the Erasmus Medical Center Rotterdam approved the 
study protocol.
Study design and methods
All eligible subjects received open-label oral EC-MPS 720 mg twice daily for 6 weeks 
followed by 360 mg twice daily for 6 weeks, according to a previous treatment protocol. 
This study followed the treatment protocol as previously reported by Geilen et al. in 
their clinical trial with MMF [9]. Subjects were not permitted to use any active topical or 
other systemic antipsoriatic therapy, except indifferent emollients during the period of 
the study from baseline till week 24. Subjects discontinued any systemic antipsoriatic 
treatment for 4 weeks and any topical antipsoriatic treatment for 2 weeks prior to study 
entry (‘wash out period’). Women who are not using oral contraception were required 
to be taking contraceptive drugs during the study and to agree to continue this until at 
least 6 weeks after completion of the study.
PASI 75% and PASI 50% at week 6 and 12 were used as primary endpoints and were both 
followed up till week 24. The relapse rate was also assessed at week 24. Clinical and labo-
ratory assessments were performed at baseline and weeks 2,4,6,8 and 12 and follow-up 
in week 24. Clinical assessments included standard physical examination and PASI-score 
at baseline, every two weeks during the treatment period (0-12 week) and at the end of 
the follow up period (week 24) or at time of withdrawal by the same investigator and 
one research nurse. [6] Laboratory tests included liver enzymes (g-glutamyltransferase, 
aspartate aminotransferase), renal parameters (urea, creatinine), blood cell count, lipids, 
CRP and BSE. At each scoring visit patients were questioned regarding adverse events 
using a standardized format. Tolerability was assessed throughout the study, including 
analysis of adverse events, potential infections, and premature withdrawal from the 
study.
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RESULTS
Study population
In total, 20 patients (18 males, 2 females) with severe plaque psoriasis with a mean PASI 
21.9 ± 9.6 (age 45.8 ± 11.5) were enrolled in this study. Of the 20 enrolled patients, all had 
used several topical antipsoriatic therapies (i.e., glucocorticoids, calcipotriol, calcitriol, 
tazarotene), 3 had received treatment with pulsed dye laser, 19 ultraviolet-B (UVB), 14 
patients had been treated earlier with conventional systemic agents and 8 patients had 
used biologicals. (Table 1)
Clinical efficacy
At baseline, the mean PASI was 21.9 ± 9.6 (age 45.8 ± 11.5). After the first 6 weeks of high 
dose EC-MPS, the mean PASI was 14.9 ± 7.21(age 28.2 ± 6.3) and 8/20 patients achieved 
a PASI50%, but no patients scored a PASI75%. A worsening of PASI was observed in 4 
patients. Between week 6 and 12 the dose of EC-MPS was reduced by half (from 1440mg 
to 720mg daily) for the subsequent 6 weeks. At week 12, one patient achieved PASI75%. 
Of the 13 patients who were assessed at week 12, 4 showed a deterioration of their 
psoriasis compared to week 6. 8 patients completed the treatment and the 24-week 
follow-up period. 2/8 patients (25%) achieved a PASI 75% in week 24.
The relapse rate of the 8 patients who completed the 24-week follow-up period is 25% 
(2/8 patients).
Short term safety
The most commonly self-reported adverse events were itching (30%) and diarrhea 
(20%). One patient discontinued therapy in week 1 due to side effects such as headache, 
itch, pain and diarrhea. Of the laboratory test, a reversible elevation of the triglycerides 
level was noted in 6 patients and cholesterol levels in 2 patients. At week 7, one patient 
discontinued therapy because of mild liver dysfunction (γ-GT 102 U/l, ASAT (GOT) 43 
U/l). No other laboratory abnormalities were observed during the study period in the 
followed patients.
Follow up
Of the 20 eligible subjects, 13 patients finished the treatment period of 12 weeks and 
only 8/13 patients completed the 24-week open-label study. Seven patients discon-
tinued therapy before week 12. 5 patients were lost to follow-up. (Table 2) 40% (n=8) 
completed the study (week 0-24), 65% (n=13) finished the treatment period (week 12), 
35% (n=7) discontinued the study before week 12 due to worsening (10%, n=2), non-
compliance (10%, n=2), liver dysfunction (5%, n=1%) and side-effects (5%, n=1). 25% 
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(n=5) were lost to follow-up due to non-responding (5%, n=1), relapse (15%, n=3) and 
non-compliance (5%, n=1).
DISCUSSION
To our knowledge, this is the first study using EC-MPS to treat patients with moderate to 
severe chronic plaque psoriasis.
The results of this small open label pilot study showed that this two-dose EC-MSP 
regimen was not effective in the treatment of moderate to severe psoriasis. The higher 
dose of EC-MPS (1440 mg daily) appeared to be more effective than the low dose, be-
cause several patients’ psoriasis worsened after dose reduction. Some case reports and 
short series of patients have revealed the efficacy of MMF in the treatment of moderate-
to-severe psoriasis [7-13]. At usual doses, MMF is generally well tolerated. Compared 
to other immunosuppressants, such as methotrexate and cyclosporine, the lack of 
end-organ toxicity with MMF offers an important therapeutic advantage. Pedraz et al 
compared MMF with cyclosporine in a prospective, cross-over, non-randomized, two-
phase, open label study the efficacy and toxicity of MMF with cyclosporine in 8 patients 
with moderate-to-severe chronic plaque psoriasis for 16 weeks. They concluded that 
cyclosporine is more effective, fast, and predictable in its effect than MMF to control 
moderate-to-severe chronic plaque psoriasis, and that both drugs are well tolerated 
in short courses of treatment [7]. The most common side-effects of MMF include gas-
trointestinal symptoms (nausea, vomiting, diarrhea, constipation and dyspepsia) and 
bone-marrow suppression (mainly leukopenia), which are generally seen in patients re-
ceiving more than 2 g daily or who simultaneously receive other immunosuppressants. 
Comparative data for EC-MPS and MMF are mainly available in renal transplant patients, 
but not in psoriasis. EC-MPS recipients had a lower rate of serious infections and serious 
pneumonia. GI symptoms in MMF recipients reduced significantly when being switched 
to EC-MPS. GI tolerability in a randomized, double blind, multinational trial showed no 
difference between MMF and EC-MPS. [14, 15]
However in dermatological practice there are no comparative studies for adverse 
events. One prospective study with MMF involving 23 psoriasis patients showed 5 pa-
tients (22%) with transient and mild GI symptoms. One patient developed pruritus and 
another angioedema. Only one patient developed laboratory abnormalities (mild leuko-
penia). [16] Another study involving 8 patients reports anorexia, constipation, insomnia, 
meteorism, nausea, palpitations and polyuria. Every adverse event reported occurs only 
once. [7] A recent review of Orvis et al shows GI complaints (nausea, diarrhea, vomiting, 
abdominal pain, soft stools, anal tenderness, frequent stools and constipation) up to 
Chapter 7
118
20% of patients using MMF. Hematological adverse events (anemia, leucopenia and 
thrombocytopenia) occur in less than 5%. [17]
Adverse events that occurred in our 20 patients receiving the therapy were accept-
able, with no serious adverse effects regarding the severity and history. The most com-
mon adverse events were itching, diarrhea and a reversible elevation of the triglycerides 
level. In a study with EC-MPS in patients with atopic dermatitis (AD), there was no itch 
reported as adverse event, while in our study 6 patients reported itch. [18] This is most 
likely caused by the more severe pre-existing itch in AD patients.
Overall, treatment of patients with moderate-to-severe psoriasis vulgaris with EC-MPS 
720 mg twice daily may be useful therapeutic in psoriatic patients unresponsive to or 
intolerant of other conventional treatments and the biologicals. A study with high dose 
EC-MPS in long-term treatment of patients with moderate-to-severe psoriasis vulgaris 
is neccesary.
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Figure 1 Improvement of psoriasis after 4 weeks of treatment
Figure 2 Improvement of psoriasis after 10 weeks of treatment
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In this era of expensive biologics, which have gained popularity as safe, effective, and 
convenient therapies for the treatment of chronic, moderate to severe plaque psoriasis, 
costs play an important role in the decision making with regard to therapy for psoriasis. 
Sizto et al. reported in their meta-analysis that methotrexate (MTX) and ciclosporine 
were the most cost-effective treatments for moderate to severe psoriasis.[1] However, 
despite being the most cost-effective options, neither MTX nor ciclosporine is recom-
mended for prolonged use in the majority of patients because of their high potentials 
for long-term toxicity. Therefore, there is a great need for effective and low-cost treat-
ment, such as fumarates (FAE), as compared with biological treatments with long-term 
efficacy and safety. Thus, we first investigated the overall efficacy and safety of FAE. 
In Chapter 2 we summarized and critically evaluated the current evidence of the ef-
ficacy, effectiveness, and safety of FAE in the treatment of psoriasis. In total, 35 studies 
published between 1987 and 2014 and involving 3372 patients were included in this 
review. The available evidence of randomized controlled trials (RCTs) was limited. Six 
RCTs were available with relatively small sample sizes. Overall, data from the included 
RCTs seem to indicate that mean PASI decreases 42% to 66% following 12 weeks of FAE 
treatment. Gastrointestinal and flushing symptoms were usually reported during the 
first three months of FAE treatment and then typically decreased over time. However, 
several case reports were found that described rare adverse events associated with FAE 
treatment, such as an important and rare complication of progressive multifocal leuko-
encephalopathy (PML) recently described in patients with FAE treatment for multiple 
sclerosis and severe lymphocytopenia. We concluded that FAE can be used as a suitable, 
effective, cheap, and safe treatment for moderate to severe psoriasis. However a simple 
but adequate monitoring of the patient is mandatory. 
When we  compare our findings to the current literature, we see that Zweegers et 
al. [3]showed in their systematic review of real-world evidence on the effectiveness of 
biologics (adalimumab, etanercept, infliximab, and ustekinumab) and conventional 
therapies (acitretin, cyclosporine, FAE, and MTX) that, in the included retrospective stud-
ies, between 40% and 49% of patients treated with 10–20 mg of MTX weekly achieved 
PASI 75 at week 12[4, 5]; PASI 75 response was attained at week 12 by 27% of patients 
treated with a mean dose of 0.38 mg/kg/day of acitretin, 46% of patients treated with 
ciclosporine,[5] and 47% of patients treated with FAE.[4] This review showed a similar ef-
ficacy of FAE compared to other conventional therapies. Our findings also concur with 
a recent Cochrane review from Atwan et al., which included six RCTs that involved 544 
participants.[6] Five RCTs compared FAE with a placebo, and our study was the only RCT 
that compared FAE with MTX. The researchers concluded that the evidence indicates 
that oral FAE is  superior to the placebo and may be similar in efficacy to MTX. 
As previously mentioned, we compared FAE to the “gold standard” MTX to evaluate its 
efficacy and safety. MTX was the first drug approved by the US Food and Drug Admin-
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istration for the treatment of psoriasis, at a time (i.e., 1972) when there were no well-
designed studies of this agent. Despite the availability of newer biologic therapies, MTX 
has remained the gold standard systemic therapy for psoriasis for nearly five decades 
due to its efficacy and cost-effectiveness.[7] Although MTX is known to be an effective 
treatment for psoriasis, it is also known for its serious side effects, such as hepatotoxic 
and teratogenic effects, and its interactions with many other drugs. Recently, the Dutch 
public health authority issued a warning to medical professionals, particularly oncolo-
gists, rheumatologists, and dermatologists, about the use of MTX and its fatal adverse 
events, generally through prescription errors, overdoses, and lack of monitoring.[8] 
In Chapter 3, we demonstrated that FAE and MTX were equally effective. After adjust-
ing for baseline values, the absolute difference (FAE minus MTX) in the mean values at 
12 weeks was 1.4 (95% confidence interval; -2.0 to 4.7; P = 0.417). 
Inzinger et al. showed consistent findings in their retrospective analysis, whereby they 
compared the primary efficacy of MTX versus FAE under daily life conditions in patients 
with moderate to severe psoriasis treated with those drugs over a seven-year period.
[4] Among patients who completed at least three months of treatment, the response to 
primary treatment with MTX versus FAE did not differ significantly at any point in time. In 
the intention-to-treat worst-case analysis at month 3, complete remission rate, PASI90, 
PASI75, and PASI50 rates were 6%, 7%, 24%, and 39% in MTX-treated patients versus 1%, 
5%, 27%, and 44% in FAE-treated patients.
Not much is known about the effect of FAE in the treatment of arthritis psoriatica. A 
small RCT of FAE in the treatment of psoriatic arthritis shows minimal improvement of 
the arthritis.[9]
We can conclude that FAE is as effective and yet safer to use for psoriasis vulgaris 
with a more favorable benefit/risk ratio compared to MTX.[10] Therefore, we recommend 
FAE as a suitable first-line therapy for moderate to severe psoriasis,[11] as it is currently 
being used as in Germany.[12] Still, many dermatologists prefer UVB phototherapy as a 
first-line treatment for moderate psoriasis in adult patients,[13] despite the large body 
of evidence confirming the mutagenic and immunosuppressive effects of UVB radia-
tion in vitro[16–20] and extended UVB exposure seems to be one of the major risk factors 
in the induction of non-melanoma skin cancer in mice and humans.[21–24] This is why 
we especially recommend the use of FAE in young adults before or instead of using 
UVB phototherapy. Furthermore, treatment with FAE is straightforward. The tablets are 
taken up to three times daily. Only simple routine examinations are needed, while UVB 
phototherapy is time-consuming for the patient and frequent sessions are difficult for 
employed persons. For fragile or disabled patients, phototherapy while standing is not 
feasible either.  
127
General Discussion and future directions
Another reason why FAE should be used as a first-line therapy for moderate to severe 
psoriasis is because FAE does not show any interactions with metabolic drugs, like MTX 
or other systemic treatments.[14, 15] Patients with psoriasis are known to have comor-
bidities such as high alcohol consumption, obesity, hepatitis, and diabetes mellitus.[16] 
Dermatologists need a treatment that is effective, eligible for long-term treatment, and 
safe but does not interact with patients’ co-medications. Different drugs interact with 
MTX, and many patients with psoriasis have comorbidities whose combination lead to 
a higher risk of hepatotoxicity, which is in itself also a contraindication of MTX. Conse-
quently, its clinical application is restricted by severe adverse drug reactions, including 
hepatotoxicity, bone marrow suppression, and gastrointestinal ulcerations. The precise 
selection of and frequent follow-up with each patient are necessary with MTX, which is 
not the case for FAE. Therefore, FAE can be given to a broad patient population.  
However, an important limitation of therapy with FAE is the intolerable adverse events 
that lead to the discontinuation of therapy in 30%–40% of patients.[11, 17] The most com-
mon cause of early treatment discontinuation is intolerable gastrointestinal symptoms 
and, to a lesser extent, flushing symptoms. These relatively inconvenient side effects 
occur predominantly during the first few weeks of FAE treatment and require thorough 
education of the patient.[14] In order to improve the tolerability of FAE, the current guide-
lines recommend slowly increasing FAE dosage using a standardized progressive dosing 
regimen.[10, 14] In this dosing regimen, the maximum daily dosage of 720 mg of FAE is 
reached within 9 weeks. If patients have adverse events, it is advised that they increase 
the dosage more slowly, decrease the dosage, or temporarily stop using the FAE. 
Pros Cons
UVB phototherapy - effective
- can be combined with other 
systemic therapies
- only a few side-effects 
(e.g.burning)
- high risk factor: induction of non-
melanoma skin cancer
- For fragile or disabled patients, 
phototherapy while standing is not 
feasible
- time-consuming, 2-3xweek for 
approximately 32 treatments, 
which is difficult for employed 
persons
FAE therapy - effective
- safe
- straightforward (tablets are taken 
up to 3 x/daily) 
- only simple routine examinations 
are needed
- no drug interactions
- eligible as longterm therapy on a 
low dosis (1-2 tablets a day)
- Adverse events: gastrointestinal 
complaints, flushing
- Long induction period
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Fig 1. Clinical response to treatment expressed as the change from baseline Psoriasis Area and Severity 
Index (PASI) over time. FUM, fumarates group; MTX, methotrexate group. Mean ± SE changes in PASI dur-
ing treatment and follow up are shown. The mean values of PASI, with SE in parentheses, at the various 
time points are shown at the bottom. (b) The proportions of patients randomly assigned to receive either 
fumarates or methotrexate until week 20 at each time point, according to various degrees of improvement 
(50%, 75%, 90%) in PASI. [1]
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Getting back to the question posed in the introduction, if the adverse events such 
as gastrointestinal complaints and flushing were histamine induced, we speculated in 
Chapter 4 that adding a daily dosage of 10 mg of cetirizine, a histamine 1 (H1) blocker, to 
FAE would reduce the FAE-induced adverse events. However, we found that the addition 
of cetirizine did not reduce the incidence of adverse events compared with a placebo 
(84% vs. 84%, P = 1.00).[18] The types of adverse events were no different between the ce-
tirizine and placebo groups, the most common being gastrointestinal complaints (68% 
vs. 64%) and flushes (60% vs. 48%). The proportion of patients discontinuing treatment 
was not statistically different between the cetirizine and placebo groups (24% vs. 32%, P 
= 0.53). Thus, we could speculate that the mechanisms underlying FAE-induced gastro-
intestinal and flushing symptoms likely involve mediators other than a histamine, and 
a histamine may play only a minor role in the generation of adverse events associated 
with FAE. Another explanation could be that the dosage of cetirizine used in our trial 
was too low, and patients would benefit more from an intake of 10 mg of cetirizine twice 
daily, such as is sometimes used with chronic urticaria.[19] The manufacturer of cetirizine 
recommends a dosage of 10 mg daily, and it is permissible to increase the dose up to 
20 mg daily. As cetirizine inhibits histamine-induced reactions dose-dependently,[20] 
it is plausible that higher doses of the drug will be more effective in controlling the 
gastrointestinal and flushing symptoms. 
Overall, we can conclude that the mechanisms underlying the adverse events induced 
by FAE are not fully understood, except for the flushing. Recent experimental studies 
show that FAE-induced flushing is mediated through the activation of the G-protein-
coupled receptor GPR109A, located on Langerhans cells and on keratinocytes, which 
leads to prostaglandin release via cyclooxygenase-1 and -2 enzymes.[21] Further evidence 
of this mechanism comes from a clinical trial involving 56 healthy volunteers, in which 
aspirin, a cyclooxygenase inhibitor, decreased the incidence and severity of flushing 
symptoms from dimethylfumarate.[22]
However, the mechanisms leading to gastrointestinal complaints in FAE treatment are 
less understood. One hypothesis involves the FAE-triggered release of tumor necrosis 
factor (TNF)-a as a mechanism leading to gastrointestinal complaints. In a previous clini-
cal study, co-treatment with FAE and pentoxifylline, a methylxanthine derivative with 
some anti-TNF-a properties, reduced the frequency of gastrointestinal complaints.[23] 
However, this study was open label and uncontrolled, so the bias of these results cannot 
be excluded. Another potential mechanism may involve dimethylfumarate-induced al-
lergic contact mucositis of the gastrointestinal tract.[24]
Indeed, it is important to mention that, since 2013, several cases of progressive 
multifocal leukoencephalopathy (PML) have been reported during treatment with 
FAE.[25-35] PML is a severe, life-threatening condition caused by the John Cunningham 
(JC) virus. Antibodies against the JC virus are detectable in more than 80% of adults.[36] 
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PML is most probably caused through the reactivation of the latent virus.[37] The most 
common causes of reactivation are hematological malignancies, infl ammatory diseases 
such as sarcoidosis, HIV infection, immunosuppressive therapy, and treatment with im-
munomodulatory drugs such as monoclonal antibodies (e.g., natalizumab, efalizumab, 
rituximab). 
Still, the occurrence of PML as a result of therapy with FAE for the treatment of 
psoriasis is very rare. Only fi ve case reports have been published in the literature since 
2014,[26, 29, 31-34] and nine reports of PML with the use of FAE are included in the Global 
Individual Case Safety Reports database (Vigibase) of the World Health Organization as 
well as two other case reports at the Netherlands Pharmacovigilance Centre Lareb. How-
ever, extra vigilance is needed, as it is a serious condition. Prolonged lymphocytopenia 
could likely play a causative role in the development of PML. 
Recently, the European Medicines Agencies (EMA) also reviewed cases of PML occur-
ring with a mixture of dimethylfumartes and monoethylfumarates salts (Fumaderm®, 
Fumapharm AG, Switzerland) and dimethylfumarates (Psorinovo®, GMP pharmacy 
Mierlo-Hout, Netherlands). Based on their review, they supported the recommenda-
tions of the European S3-Guidelines on the systemic treatment of psoriasis. According 
to the recommendations, before starting treatment, a complete blood count should be 
performed; in the presence of values outside the normal range, treatment should not be 
started. Furthermore, blood cell counts should be monitored every four weeks during 
Figure 2. Changes in Psoriasis Area and Severity Index (PASI) during 12 weeks of fumaric acid ester (FAE) 
treatment in patients treated with FAE plus cetirizine (n = 25) or FAE plus a placebo (n = 25). Error bars show 
medians and interquartile ranges.[152]
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treatment; if the lymphocyte count drops below 0.7x109/L, the dose should be halved. 
If during a follow-up check after four weeks the lymphocyte count remains below this 
value, then treatment must be discontinued. If therapy is continued in the presence of a 
lymphocyte count below 0.7x109/L, the risk of PML cannot be ruled out. We can strongly 
advise dermatologists to follow these recommendations.
We know that FAE is one of the most commonly used systemic treatments for psoria-
sis in Germany, where they are only licensed for the treatment of moderate to severe 
psoriasis as an effective, safe, and cost-effective long-term therapy.[38] Despite the 
fact that FAE is not registered in the rest of the world,  it is increasingly being used as 
unlicensed treatment in several European countries, including the UK,[39] Ireland,[11] the 
Netherlands,[2] Austria,[40] and Italy.[41, 42]
To obtain better insights into the use of FAE by Dutch dermatologists in the Neth-
erlands, we conveyed in Chapter 5 a cross-sectional postal survey. The results of this 
survey demonstrated that FAE is popular in use amongst Dutch dermatologists. A total 
of 189 (63%) of the responders indicated that they prescribed FAE for the treatment of 
psoriasis, whereas 103 (35%) of the dermatologists indicated (almost) never prescribing 
FAE. The most important reasons for not prescribing FAE were lack of experience dur-
ing residency, no experience, and FAE not being registered in the Netherlands. Twenty 
(19.4%) of the 103 respondents indicated that there were no thinkable circumstances 
under which they would be willing to prescribe FAE. The remaining 83 (81%) state they 
would be willing to prescribe FAE for patients who did not respond to other systemic 
therapies or when more clinical studies were under taken. The 189 (63%) dermatologists 
who did prescribe FAE did so mainly because of positive experiences with the therapy 
and because of few serious adverse events due to its long-term effectiveness and safety. 
Overall, a large proportion of the dermatologists in our survey indicated prescribing 
FAE, although it is not registered yet in the Netherlands and are magisterially prepared 
in the absence of industrial production according to good manufacturing practice 
(GMP) standards. 
At this point, we know and have proven that FAE is an effective and relatively safe 
treatment for psoriasis and that FAE is used by dermatologists for the treatment of 
psoriasis despite the fact that it is not licensed. We also identified two main reasons why 
some dermatologists are hesitant to prescribe FAE; in addition to the sometimes very 
inconvenient adverse events, such as gastrointestinal complaints and flushing, there is 
a long induction period whereby clinically meaningful improvement is seen just after 6 
to 8 weeks of therapy. This has an impact on compliance, which is already affected by 
several adverse events, such as flushing and diarrhea occurring in the induction phase 
of the FAE therapy. 
In Chapter 6, we hypothesized that the introduction of an induction-combination 
therapy with FAE and ciclosporine, with its rapid efficacy, could offer a good alternative 
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for patients with moderate to severe psoriasis who need to quickly reduce their disease 
severity. Such an approach could also enhance the patient’s compliance, and he/she 
would be more willing to continue FAE therapy. Little is known about combining FAE with 
other systemic therapies, such as ciclosporine. Wilsmann-Theis et al. recently described 
two patients with severe psoriasis vulgaris being treated with a combination of FAE and 
ciclosporine, whereby therapy with ciclosporine was stopped in one patient as soon 
as 6 weeks after achieving a PASI reduction from 12.0 to 3.0.[44] In 2004 Balasubramiam 
et al. retrospectively analyzed the records of patients who had received FAE for severe 
psoriasis either alone (in two cases) or along with other systemic medications (in 10 
cases). Of the 12 patients treated with FAE, one taking a very low dose discontinued the 
drug very early due to flushing. The other 11 patients all demonstrated an improvement 
in psoriasis after starting FAE. Nine patients received FAE in combination with other sys-
temic therapies, including ciclosporine, acitretin, hydroxyurea, and methotrexate. Seven 
achieved useful overall reductions in the dose of the other drugs. In two patients, severe 
psoriasis was controlled using FAE alone. There was no evidence of drug interactions.
[45] Wain et al. performed a single-center, open, nonrandomized, prospective study with 
80 patients, of which 59% were taking a concomitant oral anti psoriatic agent, such as 
MTX, ciclosporine, hydroxyurea, and MMF; 20% achieved PASI 50, 8% PASI 75, and 4% 
PASI 90 on intention-to-treat analysis at 3 months with an overall, statistically significant, 
reduction in PASI from 13.9 + or - 9.0 to 11.3 + or - 9.2 (P < 0.0001). In addition, by 3 
months, 36% of concomitant anti-psoriatic medication had been stopped, and 25% of 
doses had been reduced without a loss of disease control. The researchers concluded 
that FAE can allow dose reduction, and subsequent cessation, of other, potentially more 
toxic agents.[17]
Figure 3. Overall satisfaction per treatment (as monotherapy).[164]
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The updated European S-3 guidelines for the treatment of psoriasis currently do not 
recommend the combination of FAE with other systemic medications, mainly because 
of medical professionals’ lack of experience in combining such medications.[10, 14] Thus, 
when a patient has to discontinue treatment with FAE, we tried to find alternatives to the 
common systemic therapies, such as to ciclosporine with a milder and a more favorable 
risk/benefit ratio. Mycophenolate mofetil (MMF) has shown efficacy in the treatment 
of autoimmune and inflammatory skin disorders, including atopic dermatitis, subacute 
cutaneous lupus erythematosus, and psoriasis.[46, 47] To reduce the gastrointestinal ad-
verse events of MMF, enteric-coated mycophenolate sodium (EC-MPS) was designed to 
delay the release of mycophenolic acid (MPA) in the small intestine. At a dose of 720 mg, 
EC-MPS exhibits equivalent MPA exposure and maximal MPA concentration to 1000 mg 
of MMF.[48] 
In Chapter 7, we examined the clinical efficacy and safety profile of EC-MPS in patients 
with psoriasis vulgaris. EC-MPS has shown to inhibit lymphocyte proliferation and 
indirectly reduce the hyperproliferation of epidermal keratinocytes. Meanwhile, the 
choice of other systemic treatments besides biologics and the conventional therapies 
are limited. In an open-label pilot study, we treated 20 patients with a PASI >10. They 
received 720 mg of EC-MPS twice daily for 6 weeks followed by 360 mg twice daily for 
another 6 weeks. Patients who completed 12 weeks of treatment were followed up for 
an additional 12 weeks. Eighteen men and two women (mean age 46 years) entered the 
study. Sixty-five percent (13/20) finished the treatment period. By week 6, no patient had 
achieved PASI 75%, and 8 of the 20 patients achieved a PASI 50%. Compared to week 
6, 4 of the 13 showed a deterioration of their psoriasis at week 12. Twenty-five percent 
(2/8) achieved PASI 75% in week 24. We concluded that EC-MPS did not seem effective 
as monotherapy for moderate to severe psoriasis, but might be used at a dosage of 1440 
mg daily in well-selected patients with treatment-resistant psoriasis. 
FUTURE DIRECTIONS
Psoriasis is a chronic inflammatory skin disease, and patients are in need of a long-term 
maintenance treatment that is effective, safe, and not limited by issues of toxicity. Cost-
effectiveness on the other hand is another important responsibility of dermatologists in 
this era of expensive biologics in the evaluation for psoriasis treatments.[1] Biologics are 
developed to target single cytokines or intracellular key proteins implicated in psoriasis. 
Ustekinumab, an interleukin interleukin (IL)-12/23 antagonist, was the first anti-cytokine 
biologic used exclusively by dermatologists and is now being established for PsA. 
Secukinumab is the second biologic approved by the US Food and Drug Administration 
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(FDA) in January 2015 that selectively binds to IL-17A and inhibits interaction with the 
IL-17 receptor. 
FAE, on the other hand, seems to deplete glutathione in circulating immune cells,[49] 
which induces the expression of the anti-inflammatory protein heme oxygenase 1 (HO-
1).[50] In turn, this results in the inhibition of the pro-inflammatory cytokine production 
of TNF-α, interleukin (IL)-12, and IL-23, and FAE has been ascribed to, along with other 
immunomodulation effects, inducing TH-17 cell differentiation, which results in the in-
hibition of IL-17 expression.[51] This is a great reason why dermatologists should use FAE 
as a first-line therapy. Indeed, FAE targets multiple pathways and have multiple immune 
modulating effects. FAE can compete with MTX and biologics in effectiveness. However, 
the side effects are minimal, and long-term treatment is simple, cheap, effective, and 
safe. Therefore, based on all these findings, FAE should obtain a place as a first-line treat-
ment in psoriasis, preferred above UVB phototherapy use, especially in young adults, as 
we know that UVB phototherapy has mutagenic and immunosuppressive effects and 
is very time consuming, which again results in patients’ non-compliance. Using FAE as 
a first-line treatment favors the patient as well as the society. The major reason why 
dermatologists are hesitant to use FAE is the off-label use. The registration of FAE by 
regulatory agencies, like EMEA, would certainly make dermatologists feel more confi-
dent in prescribing FAE. 
In 2013, a FAE formulation containing delayed release DMF (BG-12, Biogen Idec, Cam-
bridge, MA, U.S.A.) was approved by the US FDA for the treatment of multiple sclerosis 
(MS).[51, 52] The nervous system and neuronal factors promote inflammation in psoriasis 
lesions, which are characterized by a high density of nerves and an increased expression 
of neurotrophins.[53] The Nrf2 pathway has an important anti-oxidative function and is 
involved in the epidermal barrier function.[54] FAE seems to induce the activation of the 
Nrf2 pathway, which is a FAE-specific effect,[51] making FAE the first modern therapy clini-
cally effective for both psoriasis and MS, unlike established biologics.[50, 52, 55] The BG-12 
FAE-formulation registered for MS was also in Phase III development for the treatment 
of psoriasis, but for unknown reasons the development of BG-12 in psoriasis seems to 
have been interrupted.[56, 57]  
Interestingly, the costs of the registered FAE formulation containing delayed-release 
DMF, BG-12 by Biogen Idec, are 34.06 € per 240 mg versus the same off-label FAE formu-
lation containing delayed-release DMF, Psorinovo®, made by the local GMP pharmacy 
Mierlo-Hout, Netherlands, which costs 1.37 € per 240 mg—a difference of 67% in price. 
In other words, the licensing of FAE has increased costs as high as the costs of the pres-
ent biologics. Biogen Idec has priced this drug at 49,541 € per patient per year. Biogen 
Idec is not setting the price of Tecfidera based on the costs of producing it as chemical 
suppliers charge 51.55 € per 1000 grams of DMF. Rather, the high price has been set 
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based on the value of this product in treating MS based on the benefits for patients and 
the savings to healthcare systems in treating this disease. 
A few different FAE formulations are in use for psoriasis. To date, only one of them, 
Fumaderm®—a mixture of DMF and the calcium, magnesium, and zinc salt of MEF—has 
been registered in Germany. Two strengths of tablets are available: Fumaderm® initial 
105 mg tablets containing 30 mg of DMF and 75 mg of MEF salts and Fumaderm 215 
mg tablets, which contain 120 mg of DMF and 95 mg of MEF salts. DMF is thought to 
be the active FAE component in Fumaderm treatment, although a double-blind study 
comparing DMF monotherapy with combination therapy of DMF and MEF salts showed 
no statistically significant differences in efficacy between the two FAE formulations.[58] In 
the Netherlands, dermatologists have the ability to prescribe different unlicensed Dutch 
FAE formulations containing DMF and calcium-MEF, DMF, or DMF in slow release.[59, 60] 
Several large RCTs are currently being conducted to evaluate novel FAE formulations 
that only contain DMF. These studies and future studies are necessary to improve the 
FAE formulation, thereby improving the tolerability of FAE. The dose-dependent and 
treatment-limiting side effects of FAE therapy are the most common cause for early 
treatment discontinuation, especially the intolerable gastrointestinal complaints and, to 
a lesser extent, flushing symptoms. Changes in laboratory tests during FAE are usually 
mild in severity and transient; thus, in the majority of cases, FAE treatment discontinua-
tion is not necessary.[10, 61] A possible solution to these gastrointestinal complaints could 
be the oral administration of 10 mg of Cetirizine twice daily. 
Furthermore, to date, only one study has suggested that FAE induces an allergic 
contact mucositis of the gastrointestinal tract. Recently, the position of the gut micro-
biome in the pathogenesis of inflammatory diseases has attracted our attention.[62-64] 
Gut dysbiosis may contribute to psoriatic arthritis through the overgrowth of inflam-
matory strains of bacteria and yeasts, the reduction of tolerogenic strains including F. 
prausnitzii, or a combination of both.[63] Dysbiosis in the intestine can determine the 
direction of differentiation of naive CD4+ T cells into either effector T cells or regulatory 
T cells (Tregs) while an imbalance can lead to chronic inflammation in the joints, skin, or 
gut.[63] Additional future studies need to be performed to investigate the effects of FAE 
on the gut microbiome.
Recently, in 2014, apremilast (Otezla, Celgene), a selective small molecule inhibitor of 
phosphodiesterase 4, was approved by the US FDA for treating patients with moderate 
to severe plaque psoriasis and psoriatic arthritis. Like FAE, it is an orally administered 
medication that has been shown to have a lower efficacy in plaque psoriasis than FAE, 
but it is especially effective in nail and scalp psoriasis.[65] For a patient suffering from 
significant nail, skin, and joint disease, a combination of apremilast with FAE—two small 
molecules—could be of high interest because FAE targets the plaque psoriasis and 
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apremilast the psoriatic arthritis and nail involvement. Both drugs are easy in use and 
considered safe with a favorable risk/benefit profile.
Speaking of combination therapy, nowadays, many dermatologists combine biologics 
with conventional systemic therapies because monotherapy with a biologic alone is not 
as promising as claimed when the first biologicals came on the market. A combination 
can result in greater reduction in disease severity. The combination of etanercept and 
MTX is more effective than monotherapy with either medication. In addition, combining 
infliximab with MTX results in greater efficacy than infliximab alone. With concomitant 
use of acitretin, the dosing of etanercept can be reduced to maintain similar levels of ef-
ficacy. Short-term cyclosporine use has been combined with etanercept or adalimumab 
to control psoriasis flares. Based on the expert opinion of the Medical Board of the Na-
tional Psoriasis Foundation, the preferred order for combining a second modality with 
biologics is a combination of biologic and MTX, biologic and acitretin, and then biologic 
and phototherapy.[66] However, all these second modalities show high toxicities and 
have no favorable adverse event profiles. Thus, caution and serious safety monitoring 
are needed when combining them with therapies such as MTX. As we have proven that 
FAE is equally effective as MTX, but with a more favorable safety profile, dermatologists 
should consider combining a biologic with FAE as a first choice before considering using 
other modalities such as MTX, if monotherapy with the biologic alone is not sufficient.[44]
Although combinations of FAE with other systemic treatments are very attractive from 
a theoretical point of view, we have to make some remarks regarding the lack of good 
studies.[10, 44] We have to rely on experience out of daily practice. However, FAE does not 
have significant immunosuppressive effects or show any drug interactions, making it 
preferable to other systemic treatments in the case of combination treatment. But clini-
cal trials with a combination of FAE and biologics are necessary future steps. An interest-
ing future clinical trial could investigate the efficacy of treatment with a combination 
of an IL 17 inhibitor such as secukinumab (Consentyx ®, Novartis) and FAE for the first 
6 months, with discontinuation of the biologic at 6 months and continuation with FAE 
as maintenance therapy. Another interesting combination is FAE with pulsed dye laser 
(PDL) treatment. Single plaque lesions left over after achieving PASI 75 can safely and 
effectively be treated with PDL.[67, 68]
FAE is definitely a suitable first-line therapy for plaque psoriasis, but it also has certain 
disadvantages, such as its long induction period of nearly 6 to 8 weeks due to its recom-
mended dosing schedule, which can have an impact on compliance. A combination of 
cyclosporine with FAE for the first 12 weeks, as we have shown in Chapter 2.4, can give 
quick satisfactory improvement, which will certainly improve compliance.
Like other immuno-modulating drugs, FAE should have potential benefit in the ap-
plication for other immune-mediated diseases. FAE has furthermore shown efficacy in 
other inflammatory diseases such as MS, for which FAE received approval by the FDA 
137
General Discussion and future directions
for the treatment of relapsing forms of MS. A few case reports have shown the improve-
ment of cutaneous forms of lupus erythematodus and sarcoidosis with off-label use of 
FAE through its immunomodulatory mechanism.[69, 70] Future studies are necessary to 
investigate the efficacy of FAE in other inflammatory diseases.
In conclusion, FAE has proven its efficacy in psoriasis, especially plaque type; with its 
favorable risk/benefit ratio, it is a definite candidate for first-line treatment in moderate 
to severe psoriasis. We recommend the use of FAE as a first-line therapy, especially in 
young adults. Patient education on the nature of the adverse events prior to starting 
treatment (e.g., types, severity [PML], frequency, transient nature), positive encourage-
ment, and the emphasis of product efficacy and the importance of staying on therapy are 
key management strategies in treatment utilizing FAE. Approval through the regulatory 
agencies, the improvement of the tolerability, and the optimization and standardization 
of the FAE formulation should take place in the near future to ensure an improvement 
and increase in the use of FAE.
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SUMMARY
Chapter 1 presents a general introduction to this thesis. Psoriasis vulgaris is recognized 
as the most prevalent autoimmune disease caused by inappropriate activation of the 
cellular immune system. It is universal in occurrence, although the worldwide preva-
lence varies between 0.6% and 4.8%. Environmental factors such as stress, medication, 
trauma, or smoking and genetic factors trigger the production of pro-inflammatory 
cytokines and chemokines and maintain inflammatory processes in the skin. The most 
common form is plaque psoriasis, which can be present in combination with psoriatic 
arthritis, which can also be considered as its own entity.
In the introduction, we explained about the four treatment modalities, which are 
divided by increasing order of potency into: 1). topical therapy, 2). phototherapy, 3). 
systemic therapy, and 4). biologics.
Although a wide variety of treatment options are available, there is still a need for a 
simple, safe, and effective long-term therapy. We explain about fumarates (FAE)—ester 
derivatives of fumaric acid that are small molecules with immunomodulating proper-
ties—and outline their current position in plaque psoriasis as well as highlighted their 
necessity in an era of worldwide escalation of healthcare costs and the high expense of 
continuous approval of new biologics as a safe, effective, and low-cost treatment.
Chapter 2 provides a systematic review in which we summarized and critically 
evaluated the current evidence of the efficacy, effectiveness, and safety of FAE in the 
treatment of psoriasis. Our goal was to provide a comprehensive summary and appraisal 
of available studies that reported the clinical effects of FAE in psoriasis patients. We 
included 68 articles. Seven RCTs (449 patients total) had an unclear risk of bias and were 
too clinically heterogeneous to allow a meta-analysis. Overall, mean psoriasis area and 
severity index decreased by 42% to 65% following 12–16 weeks of treatment. In addi-
tion, 37 observational studies (3457 patients total) supported the RCT findings, but most 
were uncontrolled with a high risk of bias. Commonly reported adverse events were 
gastro-intestinal complaints and flushing, leading to treatment withdrawal in 6% to 40% 
of cases. Rare adverse events were renal Fanconi syndrome and progressive multifocal 
leukoencephalopathy. Long-term studies and those comparing other treatments were 
lacking.
We concluded that low-quality evidence exists for recommending the use of oral FAEs 
in the treatment of plaque psoriasis in adult patients. Studies focusing on long-term 
safety and comparisons to systemic psoriasis treatments could lead to a better position-
ing of FAE as a psoriasis treatment.
Chapter 3 compares FAE to the past and present “golden standard” therapy methotrex-
ate (MTX) in a randomized controlled trial comparing the effectiveness and the adverse 
events of both treatments. Sixty patients with moderate to severe psoriasis vulgaris were 
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randomly assigned to treatment for 16 weeks with either methotrexate (30 patients; 15 
mg per week) or FAE (consisting of DMF and salts of MEF; 30 patients; 30 mg, followed 
by 120 mg according to a standard progressive dosage regimen) and were followed up 
for 4 weeks. After 12 weeks of treatment, the mean ± SD PASI decreased from 14·5 ± 3·0 
at baseline to 6·7 ± 4·5 in the MTX group, whereas it decreased from 18·1 ± 7·0 to 10·5 ± 
6·7 in the FAE group. After adjustment for baseline values, the absolute difference (FAE 
minus MTX) in the mean values at 12 weeks was 1·4 (95% confidence interval; -2·0 to 4·7; 
P = 0·417). Thus, we concluded that MTX and FAE were equally effective in the treatment 
of patients with moderate to severe psoriasis. No serious or irreversible adverse events 
were observed in any of the patients.
Chapter 4 evaluates whether the addition of cetirizine, an oral histamine-1 recep-
tor antagonist, to FAE would reduce the incidence of adverse events as 30%–40% of 
patients need to discontinue FAE treatment due to intolerable adverse events. Using a 
double-blind, placebo-controlled trial, we randomized patients with psoriasis with PASI 
≥ 10 starting an FAE up to a dose of 720 mg of DMF per day 1:1 to receive either an 
additional 10 mg of cetirizine once daily (n = 25) or a placebo (n = 25) for 12 weeks. In 
total, 50 patients (33 male, 17 female; median age 44 years) were enrolled. The addition 
of cetirizine did not reduce the incidence of adverse events compared with the placebo 
(84% vs. 84%, P = 1.00). The types of adverse events did not differ between the cetirizine 
and placebo groups, and the most common types were gastrointestinal complaints (68% 
vs. 64%) and flushes (60% vs. 48%). The proportion of patients discontinuing treatment 
was not statistically different between the cetirizine and placebo groups (24% vs. 32%, 
P = 0.53). The results showed that the addition of 10 mg of cetirizine orally once daily to 
the FAE treatment did not reduce adverse events in patients with psoriasis during the 
first 12 weeks of treatment.
Chapter 5 presents a cross-sectional postal survey to obtain insights into the use of 
FAE by Dutch dermatologists in the Netherlands. An anonymous survey was posted to 
all Dutch dermatologists (600). In this survey, data were collected on the extent of FAE 
use, the reasons for use, the reasons for non- or limited use of FAE, and the perception 
of FAE as a monotherapy with regard to the effectiveness, safety, adverse events, and 
overall satisfaction. 300 respondents is considered a proper sample size to determine 
the level of response. Ultimately, 63% of the 300 respondents indicated prescribing 
FAE for the treatment of psoriasis. About 37% of the respondents indicated that they 
(almost) never prescribed it. Biologics were considered to be the most effective therapy. 
FAE was regarded as the safest therapy followed by the rest at some distance and was 
generally well tolerated by the patients, similar to that for methotrexate according to 
the respondents. This study showed that a large proportion of Dutch dermatologists 
prescribed FAE, which was considered to be effective, safe, and with a favorable risk/
benefit profile compared with other systemic therapies, such as MTX and biologics.
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Chapter 6 proposes an alternative induction therapy with a combination of FAE and 
cyclosporine (CsA) for approximately the first 12 weeks because clinically meaningful 
improvement is seen just after 6 to 8 weeks of therapy, which is a reason for patients 
with severe psoriasis to discontinue their treatment with FAE in an early stage due to 
its slow efficacy due to the incremental dosage regimen. We introduced an alternative 
induction scheme with a relatively low adverse event profile. We suggested that FAE can 
be given according to the established dosage scheme starting with 120 mg once daily, 
followed by CsA started at 5 mg/kg daily. CsA can be stopped after reaching 80% from 
the maximum dosage of FAE depending on the PASI reduction or with a PASI reduction 
of 50%, but not later than week 12. FAE can be continued according to the established 
dosage scheme to a maximum dosage of 740 mg per day as a single treatment. We 
expected improvement of the PASI score (PASI 50%) after 2 weeks with 120 mg of FAE 
in combination with CsA, which will enhance the overall adherence. The dosage of 
FAE is dependent on each individual patient and his/her response to therapy and can 
be managed during the long-term maintenance treatment by lowering or increasing 
the dosage by not more than one tablet of 120 mg daily per week. Laboratory, urine 
analyses, and blood pressure measurements should be performed as recommended by 
the guidelines. Despite limited experience in combination therapy with FAE and CsA, 
we believe that this alternative treatment induction scheme can be beneficial and a 
fast, cost- effective, and safe alternative, especially compared to the more expensive 
biologics.
In Chapter 7, we evaluate the efficacy of mycophenolate sodium (Myfortic®) as a 
legitimate alternative therapy for plaque psoriasis in case patients need to stop FAE due 
to adverse effects. Enteric-coated mycophenolate sodium (EC-MPS) is similar to CsA, but 
without the serious side effects, such as nephrotoxicity. In an open-label pilot study, 
we treated 20 patients with PASI >10 who received 720 mg of EC-MPS twice daily for 
6 weeks followed by 360 mg twice daily for another 6 weeks. Patients who completed 
12 weeks of treatment were followed up for an additional 12 weeks. Eighteen men and 
two women (mean age 46 years) entered the study; 65% (13/20) finished the treatment 
period. By week 6, no patient achieved PASI 75%, although 8 of the 20 patients achieved 
PASI 50%. Compared to week 6, 4 out of 13 patients showed a deterioration of their 
psoriasis at week 12. Twenty-five percent (2/8) achieved PASI 75% in week 24. We con-
cluded that EC-MPS did not seem to be effective as monotherapy for moderate to severe 
psoriasis, but might be used at a dosage of 1440 mg daily in well-selected patients with 
treatment-resistant psoriasis.
Finally, Chapter 8 discusses the main findings of the studies presented in this thesis 
put them into perspective. In addition, we describe the study’s limitations and offer 
recommendations for future research and advice the use of FAE as a first line therapy for 
moderate to severe psoriasis vulgaris.
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SAMENVATTING
Hoofdstuk 1 betreft een algemene inleiding tot het onderzoek dat in dit proefschrift 
gepresenteerd wordt. Psoriasis vulgaris wordt gezien als een van de meest voorko-
mende auto-immune ziekten. Psoriasis wordt veroorzaakt door een disregulering van 
het cellulaire deel van het humane immuunsysteem. De dermatose psoriasis komt 
wereldwijd voor, echter de prevalentie tussen de verschillende geografische gebieden 
varieert tussen 0,6% en 4,8%. Omgevingsfactoren zoals stress, medicatie, trauma en 
roken spelen naast een genetische predispositie een rol resulterend in de productie van 
pro-inflammatoire cytokines en chemokines met als gevolg het ontstaan van voorna-
melijk T-cel gemedieerde inflammatoire processen in de huid.
De meest voorkomende klinische vorm is psoriasis en plaque. Dit fenotype kan in 
combinatie met arthritis psoriatica als een eigen entiteit worden beschouwd.
In de inleiding worden de vier belangrijkste behandelingen beschreven. Zoals veelal 
gebruikelijk worden de therapieën gerangschikt in volgorde van oplopende effectivi-
teit: 1). lokale therapie, 2). lichttherapie, 3). conventionele systemische therapie, en 4). 
biologics.
Hoewel het therapeutisch areaal een brede waaier van verschillende mogelijkheden 
biedt, bestaat er zeker nog behoefte aan een eenvoudig toepasbaar, veilige en effec-
tieve therapie welke ook langdurig zonder hinderlijke en / of schadelijke bijwerkingen 
kan worden toegepast.
Wij hebben ons verdiept in de stof fumaarzuur, de zogenaamde fumaraten, als 
potentieel middel dat in principe aan veel van deze criteria voldoet. Fumaraten (FAE)-
ester derivaten of fumaarzuur zelf zijn kleine moleculen met immuno-modulerende 
eigenschappen welke al decennia lang bij de behandeling van psoriasis, in het bijzonder 
psoriasis en plaque, als off-label medicijn worden toegepast.
Een overzicht van deze toepassingsmogelijkheden wordt gegeven en wij benadruk-
ken de potentie van FAE mede vanuit de optiek in een tijdperk waarin wereldwijd de 
kosten van de gezondheidszorg escaleren en waarop de behandeling van psoriasis 
zeker geen uitzondering vormt. De hoge kosten van de toelating van nieuwe biologicals 
als een veilige, effectieve behandeling is bij psoriasis, net als bij vele andere immuun 
gemedieerde zieketen als reumatoïde artritis en de ziekte van Crohn, de oorzaak van de 
exponentieel gerezen kosten. Dit rechtvaardigt FAE als goedkoop alternatief genees-
middel bij de behandeling van psoriasis grondig te overwegen.
Hoofdstuk 2 geeft een systematisch review waarin het huidige bewijs van de werk-
zaamheid, effectiviteit en veiligheid van FAE in de behandeling van psoriasis samengevat 
en kritisch geëvalueerd wordt. Ons doel is een  uitgebreide samenvatting en beoorde-
ling te geven van de beschikbare studies die de klinische effecten van FAE bij psoriasis 
patiënten beschrijft. Wij konden 68 artikelen includeren, waarvan zeven RCT’s met in 
Chapter 9
150
totaal 449 patiënten. Al deze studies hebben echter onvolkomenheden en daardoor een 
risico op een vooroordeel (bias) en zijn ook klinisch te heterogeen om een meta-analyse 
mogelijk te maken. Wel kan vanuit dit overzicht een aantal belangrijke data gegenereerd 
worden: over het geheel genomen daalde de gemiddelde Psoriasis Area and Severity 
Index (PASI) met 42% tot 65% na 12-16 weken behandeling. Daarnaast, bevestigden 
37 waarnemingsstudies (3457 patiënten in totaal) de resultaten van de RCT’s. Echter 
de meeste van de waarnemingsstudies betreffen ongecontroleerd onderzoek met een 
hoog risico op bias.
Vaak vermelde bijwerkingen zijn gastro-intestinale klachten en opvliegers hetgeen 
leidt tot het voortijdig staken van de behandeling in 6% tot 40% van de gevallen. Zeld-
zame, doch ernstige bijwerkingen zijn het renale Fanconi-syndroom en progressieve 
multifocale leuko-encefalopathie.
Het ontbreekt zowel aan lange-termijn studies als aan studies die FAE vergelijken met 
andere en bij voorkeur standaardbehandelingen voor psoriasis.
Wij concluderen dat door de matige kwaliteit van de beschikbare literatuur onvol-
doende bewijs bestaat voor een evidence based gebruik van orale FAE bij de behande-
ling van psoriasis en plaque bij volwassen. Hierdoor is het op dit moment onmogelijk 
om op basis van de gewenste bewijskracht verkregen uit degelijke studies FAE te 
positioneren in de therapeutische waaier voor de behandeling van psoriasis.
Hoofdstuk 3 vergelijkt FAE met de nog immer geldende goud standaard behandeling 
voor psoriasis en plaque al dan niet in combinatie met een artritis psoriatica: metho-
trexaat (MTX).
Door het uitvoeren van een prospectief gerandomiseerde gecontroleerd onderzoek, 
een zogenaamde RCT, waarbij de effectiviteit en bijwerkingen van beide behandelin-
gen, FAE en MTX, objectief worden vergeleken, wordt de werkzaamheid en tolerantie 
van FAE getoetst aan de goud standaard. Voor dit onderzoek werden zestig patiënten 
met matige tot ernstige psoriasis vulgaris geselecteerd. Naar willekeur werd de patiënt 
16 weken met ofwel MTX (30 patiënten; 15 mg per week) dan wel FAE (bestaand uit DMF 
en zouten van MEF; 30 patiënten, 30 mg, gevolgd door 120 mg volgens een standaard 
opbouwschema) behandeld. Hierna werd een follow-up van 4 weken in acht genomen.
Na 12 weken behandeling was de gemiddelde PASI (± sd) van 14·5 ± 3·0 bij aanvang 
gedaald tot 6·7 ± 4·5 in de MTX groep en in de FAE groep van 18·1 ± 7·0 naar 10·5 ± 6·7. 
Na correctie van de uitgangswaarden, werd het absolute verschil (FAE minus MTX) van 
de gemiddelde waarden bij 12 weken behandeling berekend: 1·4 (95% betrouwbaar-
heidsinterval, -2·0 versus 4·7; P = 0·417).
De conclusie die uit deze RCT getrokken wordt is dat FAE en MTX even effectief zijn bij 
de behandeling van patiënten met matige tot ernstige psoriasis. Geen ernstige en / of 
onomkeerbare bijwerkingen werden waargenomen.
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Hoofdstuk 4 doet verslag van een onderzoek waarbij de FAE behandeling wordt ge-
combineerd met additioneel cetirizine, een orale histamine-1 receptor antagonist, met 
het doel de meest frequente bijwerkingen te verminderen. Aangezien 30% -40% van 
de patiënten de behandeling met FAE als gevolg van deze bijwerkingen staken, is het 
voorkomen van bijwerkingen een goede mogelijkheid om de compliance te verhogen. 
In een prospectief dubbel-blind, placebo-gecontroleerd onderzoek randomiseerden 
wij twee gelijke en even grote groepen patiënten met psoriasis met een PASI ≥ 10. De 
behandeling met FAE werd gestart en verhoogd tot een dosis van 720 mg dimethyl-
fumaraat (DMF). Eén groep ontvangt tevens als adjuvans 10 mg cetirizine eenmaal 
daags (n = 25) en de andere groep een placebo (n = 25) gedurende 12 weken. In totaal 
werden 50 patiënten (33 mannen, 17 vrouwen met een gemiddelde leeftijd van 44 jaar) 
geïncludeerd. De toevoeging van cetirizine bleek niet de incidentie van bijwerkingen 
in vergelijking met placebo (84% vs. 84%, p = 1.00) te verminderen. Ook de aard der 
bijwerkingen verschilde niet tussen cetirizine en de placebo groep. De meest voorko-
mende bijwerkingen waren gastro-intestinale klachten (68% vs. 64%) en opvliegers 
(60% vs. 48%). Het percentage patiënten die de behandeling discontinueerde was niet 
statistisch verschillend tussen de cetirizine en de placebogroep (24% vs. 32%, p = 0.53).
De resultaten van deze RCT tonen aan dat de toevoeging van 10 mg cetirizine per os 
eenmaal daags de bijwerkingen van de behandeling met FAE bij patiënten met psoriasis 
gedurende de eerste 12 weken van de behandeling niet vermindert.
Hoofdstuk 5 behandelt een cross-sectionele enquête welke verricht werd om inzicht 
te verkrijgen in het gebruik van FAE door Nederlandse dermatologen. Een anonieme 
enquête werd per reguliere post verstuurd naar alle in Nederland werkzame dermato-
logen (600). In dit onderzoek werden de gegevens verzameld over de omvang van het 
gebruik van FAE, motivering over de toepassing, de redenen van het niet toepassen en 
de perceptie van de dermatoloog bij FAE als monotherapie. Alles met betrekking tot de 
doeltreffendheid, veiligheid, bijwerkingen en algemene patiënt tevredenheid. Er is met 
300 responders sprake van een goede respons.
63% van de 300 responders hebben aangegeven FAE voor te schrijven voor de be-
handeling van psoriasis. Ongeveer 37% van de responders geven aan (vrijwel) nooit 
FAE voor te schrijven. Biologicals worden beschouwd als de meest effectieve therapie 
bij psoriasis. Echter wordt FAE als de veiligste therapie gezien gevolgd door de rest 
met enige afstand welke volgens de responders bovendien in het algemeen als goed 
verdraagbaar wordt beschouwd en vergelijkbaar is aan MTX . Deze studie toont aan dat 
een groot deel van de Nederlandse dermatologen FAE voorschrijft op grond van over-
wegingen dat FAE een effectief, veilig middel is met een gunstig risico / baten-profiel in 
vergelijking met andere systemische therapieën, zoals MTX en biologics.
Hoofdstuk 6 betreft een alternatieve inductiebehandeling van FAE door dit middel te 
combineren met cyclosporine (CsA) gedurende de eerste 12 weken van de behandeling.
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Klinisch significante verbetering treedt bij FAE behandeling pas na 6 tot 8 weken op 
waardoor zichtbare resultaten pas laat optreden. Dit vormt voor een aantal patiënten 
een reden om in een vroeg stadium de behandeling af te breken. Daarom introduceer-
den wij een alternatief inductieschema met een relatief laag bijwerkingsprofiel juist met 
het doel snel klinisch zichtbaar resultaat te boeken. Uitgangspunt is dat vanaf de start 
met 120 mg DMF eenmaal daags dit gecombineerd wordt met CsA beginnend met 5 
mg/kg lichaamsgewicht per dag per os. CsA wordt gestopt wanneer 80% van de maxi-
male dosering FAE en / of een PASI reductie van 50% bereikt is. CsA wordt bovendien 
niet langer dan tot en met week 12 voorgeschreven. Wel wordt de FAE behandeling als 
gebruikelijk ook na week 12 voortgezet op basis van het standaard doseringsschema 
tot de maximale dosering van 740 mg per dag als monotherapie. Wij verwachten een 
verbetering van de PASI score (PASI 50%) na 2 weken 120 mg FAE in combinatie met CsA, 
waardoor de therapietrouw zal verbeteren.
De onderhoudsdosering van FAE is afhankelijk van elke individuele patiënt en haar 
of zijn respons hier op wordt gereguleerd tijdens door het verlagen of verhogen van 
de dosering echter met niet meer dan één tablet van 120 mg per dag per week. La-
boratorium-, urine-analyses, en bloeddrukmetingen moeten worden uitgevoerd zoals 
aanbevolen in de richtlijnen. Ondanks de beperkte ervaring met combinatietherapie 
met FAE en CsA, geloven wij dat dit alternatieve behandel-inductieschema voordelig, 
snel, kosteneffectief en een veilig alternatief. Dit vooral in vergelijking met de veel 
duurdere biologicals.
In hoofdstuk 7, evalueren wij de effectiviteit van natrium-mycofenolaat (Myfortic®) 
als een legitieme alternatieve therapie voor plaque psoriasis. Maagsapresistent natrium-
mycofenolaat (EC-MPS) is verwant aan CsA en eveneens een T-cel manipulator, maar 
zonder de ernstige bijwerkingen van CsA zoals nefrotoxiciteit. In een open-label pilot 
studie behandelden wij 20 patiënten met een PASI> 10 met 720 mg EC-MPS tweemaal 
daags gedurende 6 weken gevolgd door 360 mg tweemaal daags gedurende de vol-
gende 6 weken. Patiënten die 12 weken werden behandeld werden gedurende nog 
eens 12 weken gevolgd. Achttien mannen en twee vrouwen (gemiddelde leeftijd 46 
jaar) werden geïncludeerd. 65% (13/20) doorliepen het gehele behandeltraject. In week 
6 bereikte geen enkele patiënt een PASI 75%. 8 van de 20 (40%) patiënten bereikten wel 
een PASI 50%. Vergelijkend met week 6, constateerden wij bij 4 van de 13 patiënten een 
verslechtering van hun psoriasis op week 12. 25% van de PASI 50% groep (2/8) bereikte 
uiteindelijk een PASI 75% in week 24.
Wij concludeerden dat EC-MPS niet effectief is als monotherapie voor matige tot 
ernstige psoriasis. Echter bij goed geselecteerde patiënten met een therapieresistente 
psoriasis kan dir middel worden gebruikt in een dosering van 1440 mg per dag als een 
soort last resort therapie.
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Summary/Samenvatting
Tot slot , worden in hoofdstuk 8 de belangrijkste bevindingen van de studies in dit 
proefschrift in het juiste perspectief gezet . Daarnaast beschrijven wij de beperkingen 
van de studies en bieden aanbevelingen voor toekomstig onderzoek en raden het ge-
bruik van FAE als eerstelijnsbehandeling voor matige tot ernstige psoriasis vulgaris aan.
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List of abbreviations
LIST OF ABBREVIATIONS
Bcl2 B-cell lymphoma gene
BSA Body Surface Area
CsA Ciclosporine
CXCL Cysteine X Cysteine Ligand
CXCL8 CXC ligand 8, Interleukin 8
DMF Dimethylfumarate
EC-MPS Enteric-coated mycophenolate sodium
EMEA European Medicine Agencies
E-selectin Endothelial selectin
FAE Fumaric acid ester derivates
HLA-DR Human Leukocyte Antigen - antigen D Related
ICAM-1 Intercellular Adhesion Molecule 1
IL Interleukin
IL-1RA Interleukin 1 receptor antagonist
JC virus John Cunningham virus
MACE Major Adverse Cardiovascular Events
MEF Monoethylfumarate
MMF Mycophenolate mofetil
MPA Mycophenolic acid
MTX Methotrexate
NF-kB Nuclear Factor kappa B
NO Nitric Oxide
NQO-1 NAD(P)H Dehydrogenase, Quinone 1
Nrf2 Nuclear factor (erythroid-derived 2)-like 2
PASI Psoriasis Area Severity Index
PBMC Peripheral Blood Mononuclear Cells
PGA Physician’s Global Assessment
PML Progressive Multifocal Leukoencephalopathy
PsA Psoriatic arthritis
RCT Randomized controlled trial
TCA cycle Tricarboxylic cycle
Th cells T-helper cells
TNF-α Tumor necrosis factor α
UVB UV: 320-290 nm
VCAM-1 Vascular Cell Adhesion Molecule 1
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In this era of expensive biolog-
ics, which have gained popular-
ity among dermatologists as ef-
fective treatments for chronic, 
moderate to severe plaque 
psoriasis, there is a great need 
for an effective, safe, long-
term and low-cost therapy 
such as fumarates. 
In this book the authors have inves-
tigated its efficacy, safety, adverse-
events, popularity among Dutch 
dermatologists, combination 
therapy and alternative 
treatment options.
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